Podcasts about ipop

Send us a textAriel is a rising teenage country singer/songwriter from Arizona, known for her soulful voie and heartfelt lyrics. She began singing at 4 and has been actively performing for over eight years.In 2022 she gained recognition after winning a singing competition at IPop. Ariel continues to make a name for herself with original music , inculing her 2024 release "I will remember you"!!  y'll give her a listen www.arielfranzmmusic.comSupport the showThe David Bradley ShowHost: David Bradleyhttps://www.facebook.com/100087472238854https://youtube.com/@thedavidbradleyshowwww.thedavidbradleyshow.com Like to be a guestContact Usjulie@thedavidbradleyshow.comRecorded at Bradley StudiosProduced by: Caitlin BackesProud Member of CMASPONSERSBottled Water and Sweet Tea provided by PURITY DairyABlaze Entertainment

Welcome to the Rose Woman Podcast, where we explore the cutting edge of health, wellness, and personal empowerment. Today, we have a very special guest - Dr. Michael Snyder, a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project.He has also combined different state-of-the-art "omics" technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. Dr. Snyder is the cofounder of Personalis, SensOmics, Qbio @qbioinc, January AI, Filtricine, Mirvie, Protos, Protometrix (now part of Thermo-Fisher). Affomix (now part of Illumina).This is an episode that just might change the way you think about your health and the future of healthcare - don't miss it.In this episode, we cover:Importance of measuring health frequently while people are still healthy to detect early signs of diseaseThe use of wearables, such as smartwatches and Oura rings, plays a crucial role in early detectionBreakdown of omics concepts like genomics, proteomics, and metabolomicsThe role of hormones in aging and the impact of andropause and menopauseEmphasis on the importance of exercise and strength training for overall healthAdvancements in DNA sequencing, mass spectrometry, and wearablesThe importance of continuous data collection and the role of AI in integrating and analyzing large datasetsThe challenges of implementing proactive health monitoring in the current healthcare systemImportance of financial incentives and the role of employers in promoting health and wellnessVision for the future of healthcare with continuous health monitoring and AI-powered personalized recommendationsThe role of hormones and agingHelpful links:Michael Snyder, Ph.D. - Stanford W. Ascherman Professor of Genetics and SnyderlabGenomics and Personalized Medicine: What Everyone Needs to KnowFounder Letter: The New Science on Aging Well by Christine MasonFind Rosebud Woman on Instagram as @rosebudwoman, Christine on Instagram as @christinemariemasonFind Radiant Farms on Instagram @weareradiantfarms Hosted on Acast. See acast.com/privacy for more information.

It's been a while but we got our thoughts on what the latest news on our Entertainment pillars. We start off with our thoughts on the PS5 Pro and a few games we're looking forward to, as well as Linkin Park's new singer and the legacy of Chester Bennington, the open casting on the rebooted Harry Potter TV Series and more. We cover all this while we have our hands on the Common Space Brewery's Food Fight Hazy IPA and Mason Ale Works xSeek Beer Co.'s iPOP! Tropical fruit beer.Our handles are below:Instagram - @goldencraftcastSpotify Page - https://open.spotify.com/show/6l2mBN1CF7gs9DHZLgOJjCWe are available in every podcast platform! Feel free to comment and review!

Sarah C má 14 rokov a už sa naplno venuje spevu, herectvu aj tancu. V Los Angeles sa zúčastnila veľkej talentovej súťaže iPop, kde sedel v porote aj americký producent Manny Mijares. Toho zaujala, stretli sa aj s rodičmi a začali spolupracovať a systematicky Sarah budovať kariéru. Manny má skúsenosti s naozaj zaujímavými menami ako Snoop Dogg, Dua Lipa či Craig David a o Sarah hovorí, že je naozaj nezvyčajné natrafiť na takýto talent v tak mladom veku. A navyše s chuťou robiť viac, ako len fotky na sociálne siete. V kanáli je rozhovor aj v originálnom znení. | Dabing bol nahratý v spolupráci s AI.

Sarah C má 14 rokov a už sa naplno venuje spevu, herectvu aj tancu. V Los Angeles sa zúčastnila veľkej talentovej súťaže iPop, kde sedel v porote aj americký producent Manny Mijares. Toho zaujala, stretli sa aj s rodičmi a začali spolupracovať a systematicky Sarah budovať kariéru. Manny má skúsenosti s naozaj zaujímavými menami ako Snoop Dogg, Dua Lipa či Craig David a o Sarah hovorí, že je naozaj nezvyčajné natrafiť na takýto talent v tak mladom veku. A navyše s chuťou robiť viac, ako len fotky na sociálne siete. V kanáli je rozhovor aj s dabingom :)

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Nicole Miglis - All I See Is You 2) Loma - Pink Sky 3) Martha Skye Murphy - Pick Yourself Up 4) dear francis - touchdown (4-track) 5) Fine - Coasting 6) Sherwyn - Infinity High 7) Crumb - Side By Side 8) Opus Kink - I Wanna Live With You 9) Jessica Boudreaux - Back Then 10) Tasha - Michigan 11) 7ebra - Normal Song 12) Hinds; Beck - Boom Boom Back 13) meija; Jawny - Magic 14) J.R.C.G. - Dogear 15) Laughing - Will She Ever Be A Friend Of Mine 16) Bacchae - Next Time 17) Good News - Orange Juice In The Shower 18) Scattered Ashes - Ether 19) Sis - Mother's Grace 20) Louis Cole; Metropole Orkest; Jules Buckley - Things Will Fall Apart 21) Finom - Cyclops 22) Peter Cat Recording Co. - People Never Change - Radio Edit 23) Niques - Mate 24) Fcukers - Bon Bon

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Kee Avil - Gelatin 2) Tummyache - What You Wanna See 3) Retropxssy - All The Things 4) Emily Breeze - 1997 5) Cults - Crybaby 6) Nilüfer Yanya - Like I Say (I runaway) 7) Sam Bambery - The Burnout 8) Formal Sppeedwear - 6 Lofty Ash 9) Hamish Hawk - Big Cat Tattoos 10) Laura J Martin; Iwan Morgan - Living on the Wall 11) Font - Hey Kekulé 12) Orlando Weeks; Rhian Teasdale - Dig feat. Rhian Teasdale 13) Spangled - Crank Up The Splendour 14) Dreamwave - Void 15) Sailor Honeymoon - Bad Apple 16) Danny Rebel & The KGB - Spiral Eyes 17) Milo Korbenski - I'm a Slug 18) Mock Tudors - Hair of the Dog 19) dayaway - ghost beaces 20) Creature Canyon - Who? 21) Angélica Garcia - Gemini 22) Ebbb - Swarm

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Martha Skye Murphy; Roy Montgomery - Need 2) Winter - Sallow 3) Sofia Bolt - Martini 4) Louisa Stancioff - Alice 5) Couch Prints - Colorado 6) Twen - Stunts 7) Color Green - Four Leaf Clover 8) Suki Waterhouse - My Fun 9) Home Counties - Dividing Lines 10) Jelani Aryeh - Sweater Club 11) GIMMY - Bathrooms 12) The Pill - Bale of Hay 13) Sex Week - Angel Blessings 14) Abbie Ozard - anything for you 15) GIFT - Wish Me Away 16) Fontaines D.C. - Starburster 17) Trent Reznor and Atticus Ross; Boys Noize - "I Know" [MIXED] 18) YARD - Big Shoes 19) µ-Ziq - Hyper Daddy - Single Version 20) Hex Girlfriend - Café Culture

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Teddy Hunter - Daylight 2) Sis - Center Of The Heart 3) Kacy Hill - Damn 4) Bob Vylan; Jerub - Humble As The Sun 5) Big Special - Black Dog / White Horse Bd/Wh 6) Jane Weaver - Is Metal 7) Uche Yara - Sasha (Wake Up!) 8) Yellow Days - Finer Things In Life 9) Dogmanjones - Tuk Tuk 10) Drahla - Talking Radiance 11) Lip Critic - In The Wawa (Convinced I Am God) 12) Greg Saunier - Grow Like A Plant 13) Sinkane - Come Together 14) Megan Black - Funk For Introverts 15) Brijean - Workin' On It 16) Brutus Viii - I Didn't Ask 17) Caribou - Honey 18) Mandy, Indiana - Idea Is Best

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Future Utopia - Interplanetary Signs 2) John Grant - It's A Bitch 3) Man Man - Iguana 4) Declatel - Western Eyes 5) Boeckner - Lose 6) A Certain Ratio - Keep it Real - Single Version 7) ELLiS·D - Humdrum 8) Bad Bad Hats - My Heart Your Heart 9) Aluminum - Behind My Mouth 10) Hot Joy - Fingers on my Side 11) Lionlimb - Hurricane 12) Annie-Claude Deschênes - PHONES 13) Aaron Lee Tasjan - The Drugs Did Me 14) Bat For Lashes - Letter To My Daughter 15) Alena Spanger - All That I Wanted 16) Machinedrum; Tinashe - ZOOM 17) Michael Vincent Waller; Jlin - Return from LA II - Jlin Remix 18) Anna Prior - Fall Back 19) Nixer - The Book 20) I. JORDAN - Close To You

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Camera Obscura - We're Going to Make It in a Man's World 2) Mei Semones - Tegami 3) Rona Mac - Links Like Fists 4) Earth Flower; Ruth Garbus; Sam Gendel - Nature's Piano 5) Chanel Beads - Police Scanner 6) mui zyu - the mould 7) Miracle Worker - Leave Me Alone 8) Dehd - Light On 9) Finom - Haircut 10) La Luz - Strange World 11) Shalom - Hit That (Gets You High) 12) Ibibio Sound Machine - Pull the Rope 13) Bad Bad Hats - TPA 14) Borca; Bdab1 - CITGO 15) Jouska; Niilas - Damon Days (Niilas Remix) 16) Porij - Unpredictable 17) Ezra Collective; Sampa the Great; Joy Anonymous - JOY (Life Goes On) 18) The Illustrious Blacks - Illusion 19) Underworld; KETTAMA - Fen Violet

This week we drive...away... after getting out of the theater to review Drive-Away Dolls. We also discuss Demon Slayer: Kimetsu No Yaiba - To the Hashira Training, The Iron Claw, Halo, The Bear, Paper Moon, Avatar: The Last Airbender, and Chopper. All while drinking three different beers (fuck you Craft Beer Kings). First up we have Glitter Moon. A Imperial Hazy IPA by Revision Brewing Company, out of Spaerks, Nevada. Next we have Juuci Tart. A fruited sour by Absolution Brewing Company, out of Torrance, California. Finally we have iPOP! Tropical. A fruit beer by Mason Ale Works, out of San Diego, California. Intro and Beer Selection 0:00-22:02 Drive-Away Dolls Review 22:02-48:04 Nano Reviews 48:04-1:14:09 Outro 1:14:09-1:16:36 Subscribe to our Patreon for premium episodes! Like us on Facebook! Follow us on Apple Podcasts! Follow us on Spotify! Follow us on  Podbean! Follow us on Instagram! Follow us on TikTok! You can buy individual premium episodes on our Bandcamp! Send your questions and comments to sudsandcinemapodcast@gmail.com Logo and Artwork by @djmikeholiday

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Bat For Lashes - The Dream of Delphi 2) Magana - Paul 3) Caleb Landry Jones - Corn Mine 4) Jessica Pratt - Life Is 5) Hana Vu - Care 6) Wes Parker - Why Won't You Pick Up The Phone? 7) Glass Beams - Mahal 8) Warpaint - Common Blue 9) Work Wife - Something's Up 10) bob junior - sunshine 11) Blunt Chunks - Psyche's Flight 12) Bored at My Grandmas House - Show & Tell 13) Sheer Mag - Moonstruck 14) Mary Timony - Dominoes 15) Isobel Campbell - 4316 16) Richard Hawley - Two for His Heels 17) Girl and Girl - Hello 18) English Teacher - Nearly Daffodils 19) Pastel - Dancing On A Pin 20) Meatbodies - Billow 21) The Mysterines - Stray 22) Crinc - Crachach 23) Nadine Shah - Even Light 24) IDLES - POP POP POP 25) Psymon Spine - Bored of Guitar 26) Kim Gordon - I'm A Man 27) The Baby Seals - Vibrator 28) Drahla - Second Rhythm 29) bdrmm - Standard Tuning 30) KÁRYYN - the REAL 31) Sunna Margrét - Come With Me 32) Effy; Mall Grab - iluv 33) sunnbrella - have your say 34) Cakes da Killa; Dawn Richard - Do Dat Baby 35) Brittany Davis - So Fly

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Beth Gibbons - Floating On A Moment 2) A. Savage - Black Holes, the Stars and You 3) pencil - The Window 4) Amen Dunes - Purple Land 5) Verde Prato; BRONQUIO - Maite, Nauzu Zeharkatu 6) Superdestroyer; Pink Navel - ▣ Outer Space Disco Lemonade 7) Craig Wedren - Pronouns 8) Mk.gee - Alesis 9) This Is The Kit - Sensations in the Dark 10) Porcine - Stop The World 11) Dancer - Change 12) The Lemon Twigs - They Don't Know How To Fall In Place 13) Pylon Reenactment Society - Flowers Everywhere 14) Mannequin Pussy - Nothing Like 15) The Fauns - Mixtape Days 16) Lee "Scratch" Perry; Shaun Ryder - Green Banana 17) Little Simz - Mood Swings 18) Jlin - Auset 19) Bodysync; Ryan Hemsworth; Giraffage - Birds

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) Walt Disco - Pearl 2) Astrel K - Darkness At Noon 3) Mol Sullivan - Cannonball 4) Lutalo; Claud - Running 5) Lucy McWilliams - Follow Me 6) NewDad - Angel 7) J Mahon - Gold States 8) Les Big Byrd - Diamonds, Rhinestones and Hard Rain 9) Lock-In - Red Stripe Remedy 10) Beans - Groove 11) Holiday Ghosts - Sublime Disconnect 12) The Baby Seals - Mild Misogynist 13) Cowboy Hunters - Body Parts 14) PLAY DEAD - Thameslink 15) Sleater-Kinney - Small Finds 16) Solar Eyes - Let's Run Away 17) Talk Show - Red/White 18) Chalk - Claw 19) Lime Garden - Love Song 20) CVC - The Remortgage Anthem 21) Porij - You Should Know Me

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1. Astrid Sonne - Boost 2. Byland - Lean In 3. Bruiser Wolf - Dope Boy 4. R.A.P. Ferreira; Fumitake Tamura; Hprizm - begonias 5. pecq - out loud 6. Runnner - eleven 7. R. Missing - Make It Starry Most 8. pMad - Opinion 9. Amiture - Billy's Dream 10. Lila Ehjä - The Book 11. Royel Otis - Velvet 12. Chemtrails - Bang Bang 13. Crawling Vines - Go To Bed 14. EKKSTACY - goo lagoon 15. Hoorsees - Charming City Life 16. SPRINTS - Adore Adore Adore 17. C Turtle - Shake It Down 18. Gustaf - Starting and Staring 19. Sailor Honeymoon - Bad Apple 20. Lynks - NEW BOYFRIEND 21. Sourface - Careless Love

Breaking from traditional norms of beer, iPop  explores the concept of making a beer inspired by cocktails that doesn't taste like beer...this edition takes its inspiration from a Painkiller.

This is all about the entertainment news of The Iron Claw True story movie, GLASS Ipop girl band and LKYN Ipop boy band. --- Send in a voice message: https://podcasters.spotify.com/pod/show/tasha-monell2/message

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han sonado: 1) The Pogues; Kirsty MacColl - Fairytale of New York (feat. Kirsty MacColl) -In memoriam of Shane MacGowan- Bonus track. 2) Soho Rezanejad; Agnese Menguzzato; Simone Antonioni - Exit Blue Klein 3) Hovvdy - Bubba 4) Emma Gatrill - Offshore Disco 5) YINYANG - Kill Jester 6) @ - Soul Hole 7) WILDES - heartbreak is silent 8) Fat White Family - Religion for One 9) Symbol Soup; Kitty Fitz - Husky Dawgs 10) Katie Von Schleicher - Montagnard People 11) Holly Macve; Laura-Mary Carter - Blue Moon 12) King Casio - So Much More 13) The Hanging Stars - Let Me Dream Of You 14) bob junior; Alfie Templeman - No One Does It Better Than You 15) BIG SPECIAL - TREES 16) UCHE YARA - Sophie 17) Huw & the Greater Good - Dopamine 18) Chemtrails - Business Class War Paint 19) Teens in Trouble - You Don't Want To Mess With Me 20) LOVEBREAKERS - Dirt Nap 21) Sharp Class - Ivory Tower 22) Bad Nerves - Antidote

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han Sonado: 1) Fthmlss - Agaric 2) 박혜진 Park Hye Jin - Foreigner 3) Mount Palomar; Harry Wilkinson - Embers 4) Sleaford Mods - West End Girls 5) Jeymes Samuel; Lil Wayne; Buju Banton; Shabba Ranks - Hallelujah Heaven (feat. Lil Wayne, Buju Banton, and Shabba Ranks) 6) Mandy, Indiana - Pinking Shears 7) Laneous - Nice Work 8) Kaeto - No Body 9) Arctic Lights - Melting 10) TVAM - Ephemerol 11) Shelf Lives - All Grown Up 12) Abstract Concrete - Ventriloquist/Dummy 13) Chalk - The Gate 14) The Kartetch - Mlnw 15) Gen and the Degenerates - Famous 16) Snõõper - Powerball 17) VIAL - ur dad 18) Heartworms - May I Comply 19) Meatraffle - Lovesong Industrial Complex - Radio Edit 20) youbet - Carsick

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han Sonado: 1) Juan Wauters - P.O.V. 2) Adult DVD - Yacht Money 3) Getdown Services - Evil On Tap 4) Folly Group - Big Ground 5) Talk Show - Gold 6) Emily Yacina - Nothing Lasts 7) gglum - Easy Fun 8) Dutch Mustard - Wake Up 9) Jaws the Shark - Suff City 10) Neva Dinova - Outside 11) PACKS - HFCS 12) Hand Drawn Maps - Red and Blue 13) Omni - Exacto 14) PROJECTOR - No Guilt 15) The Rills - Bones 16) Autogramm - Plastic Punks 17) I Wish I Was a Punk Band - Let It Rest 18) KNEECAP; Grian Chatten - Better Way To Live 19) Cakes da Killa; Sevndeep - Sip of My Sip 20) Daniel Avery - Need Electric - 2023 Redux - Edit 21) Mint Julep - All Summer Long

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han Sonado: 1) Evelinn Trouble - Needy Woman 2) Emma Anderson - The Presence 3) Drop Nineteens - The Price Was High 4) Faux Real - Faux Maux 5) Yard Act - Dream Job 6) Cheekface - Largest Muscle 7) Mickey 9s - Dream 8) Dazy - Forced Perspective 9) Brigitte Calls Me Baby - You Are Only Made Of Dreams 10) Library Card - Cognitive Dissonance 11) Telehealth - Mindtrap 12) talker - TWENTYSOMETHING 13) CIEL - Talk 14) deep tan - xenomorph queen 15) Dirty Nice - Capsizing 16) Erik Nervous - Drop Dead 17) Aesop Rock - Infinity Fill Goose Down 18) H31R; JWords; maassai; Quelle Chris - Down Down Bb 19) Rangleklods - Alien 20) Delilah Holliday - Long Time Coming 21) Working Men's Club; Gabe Gurnsey - Widow - Gabe Gurnsey Remix

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han Sonado: 1) Juicebumps - Edging in Heaven 2) Girl and Girl - Strangers (Fight Night) 3) Dream Nails - Ballpit 4) Flamingods - Adana 5) Kula Shaker - Indian Record Player 6) Stay - I Can Hear The Grass Grow 7) Lilts - Too Late 8) Parliamo - Red Letter 9) Upchuck - Crashing 10) The Serfs - Electric Like An Eel 11) Tele Novella - Eggs in one Basket 12) The Exbats - Riding With Paul 13) Anna Hillburg - How Do You Make Believe 14) Meernaa - So Far So Good 15) Land of Talk - Your Beautiful Self 16) Nightbus - Exposed to Some Light 17) Proteins of Magic - Flesh It Out 18) Vanishing Twin - Afternoon X

California-based singer, songwriter, multi-instrumentalist, dancer, and actress who just released her newest single last month. She does reveal during this interview, however, that there are four more new songs coming. She has performed at the GRAMMY Teen Concert, The Fashion Life Tour, and iHeartRadio 102.7 KISS-FM Concert at IPOP, plus she talks here about having performed at the NAMM Show this past April. Aside from her music career, she is also involved in voiceover acting and on-camera acting, being most well known for being the voice of MC Swag on “LOL House of Surprises” and for her role in “Love XO.” She currently has 146 THOUSAND followers on Instagram and is closing in on a half-million combined video views on her official YouTube channel.

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han Sonado: 1) Armand Hammer; Billy Woods; E L U C I D; El-P - The Gods Must Be Crazy 2) Mo Kolours - Rockets To Mars 3) Joseph Malik - Adjust Like Dat 4) Ian Sweet - Your Spit 5) Zzzahara - I'd Like You To Leave 6) Squirrel Flower - Intheskatepark 7) Sun Mahshene - Reverie 8) Lowertown - Bline 9) Diners - Working On My Dreams 10) Slow Pulp - Gone 2 11) The Jesus Bolt - Permanent Record 12) Cat Valley - Bingo Queen 13) Thank You, I'm Sorry - Mirror 14) HotWax - Phone Machine 15) Powerplant - Grass 16) Mock Media - Modern Visions 17) Marnie Stern - Believing Is Seeing 18) Uma - La Vidente 19) G Jones - Remnant 20) Jessica Winter; Jonathan Snipes - All I Need

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Han Sonado: 1. African Head Charge - Microdosing 2. Elena Shirin - Zoom Out 3. L'Rain - Pet Rock 4. B.Miles - Separate Rooms 5. Nour - Wana 6. Earth; The Bug; Flowdan - Angels (The Bug Remix feat. Flowdan) 7. Ekiti Sound; Aunty Rayzor - Chairman 8. Mother Tongues - Worm Day 9. Kristin Hersh - Ms Haha 10. Theo Bleak - It's Not Doing Me Any Good 11. Marika Hackman - No Caffeine 12. English Teacher - The World's Biggest Paving Slab 13. MØ; The Raveonettes - Attack of the Ghost Riders 14. Home Counties - Bethnal Green 15. Slate - St Agatha 16. KennyHoopla - keep a window open// 17. Superchunk - February Punk 18. Mannequin Pussy - I Got Heaven 19. Urusei Yatsura - Kewpies Like Watermelon 20. SPRINTS - Up and Comer 21. Blues Lawyer - Have Nots

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas. Hoy especial los temas del verano (radio curie #05) y las novedades de la vuelta al cole, radio curie #06! Han Sonado: RADIO CURIE 05 1. ANOHNI; Antony and the Johnsons - It Must Change 2. Rufus Wainwright; David Byrne - High on a Rocky Ledge (feat. David Byrne) 3. Grian Chatten - Last Time Every Time Forever 4. Ursa Major Moving Group - Boundaries (For Linda) 5. Nitin Sawhney; Guy Garvey - Darling Boy (feat. Guy Garvey) 6. Jenny Lewis - Cherry Baby 7. WITCH; Theresa Ng'ambi; Hanna Tembo - Unimvwesha Shuga 8. iskwē; Nina Hagen - I Get High ft Nina Hagen 9. Jake Shears - Last Man Dancing 10. Alien Tango - Kinda Happy, Kinda Sad 11. Treeboy & Arc - Behind The Curtain 12. King Krule - Pink Shell 13. Protomartyr - Elimination Dances 14. Jean Dawson - delusional world champion 15. Genesis Owusu - Leaving The Light 16. ill peach - BLAH BLAH BLAH 17. Master Peace - Brussels 18. Hak Baker - DOOLALLY 19. Dream Wife - Social Lubrication 20. Blur - The Narcissist RADIO CURIE 06 1. Generation Feral - newborn adult 2. Holy Wave; Lorelle Meets The Obsolete - The Darkest Timeline 3. The Derevolutions - Cheetah 4. cumgirl8 - cursed angel 5. The Rain Parade - Last Rays of a Dying Sun 6. Emmett Kai - Slow Dancing On Pavement 7. Hotel Lux - Vice 8. Gen and the Degenerates - BIG HIT SINGLE 9. Folly Group - Strange Neighbour 10. Echo Ladies - Coming Home 11. Virgins - s l o w l y, l o n g 12. Brontez Purnell - No Cigarettes / Stay Monkey 13. 26fix - Stone Killer 14. Dutch Criminal Record - Oat Milk 15. Public Image Ltd. - Walls 16. Miles Kane - One Man Band 17. CARR - Spiral City 18. Jaakko Eino Kalevi - I Forget

(9/13/23) Markets rallied into Apple's iPhone reveal, then sold off yesterday; who can afford an iPhone 15? CPI for August to be released this morning (3.7% vs anticipated 3.6%). Lenders are now rolling out a 1% down payment program in hopes of reviving their business. The thing about home ownership: It's always something. How do mortgage lenders do it? They eat part of the rate up front, but YOU will pay for it on the back end. What does a larger (20%) down payment say about financial ability? The cost of home ownership goes beyond being able to afford a mortgage payment; home prices are a function of supply & demand. No one wants to sell into a housing market with 7% mortgage rates. The tricks home builders use; How "good" do Baby Boomers have it (and why)? Time to invest, bull markets; thought processes about money, managing expenses. What is an IPOP all about: It's NOT selling at a discount. (Fiscal responsibility doesn't sell products) What do 20% of Gen-Z's want to be? Social Media influencers. Switching from spending to saving mode. SEG-1: The Apple Reveal: Who Can Afford an iPhone? SEG-2: Is the 1% Down Payment a Win-win? SEG-3: The Cost of Home Ownership: Why Prices are Too High SEG-4: Why Baby Boomers have it So "Good" Hosted by RIA Advisors Chief Investment Strategist Lance Roberts, CIO, w Senior Financial Advisor Danny Ratliff, CFP Produced by Brent Clanton, Executive Producer -------- Watch today's show on our YouTube channel: https://www.youtube.com/watch?v=SGh81vUL7Aw&list=PLVT8LcWPeAugpcGzM8hHyEP11lE87RYPe&index=2 -------- The latest installment of our new feature, Before the Bell, "Rising Bottoms & Declining Tops" is here: https://www.youtube.com/watch?v=DK_yt7qpT20&list=PLwNgo56zE4RAbkqxgdj-8GOvjZTp9_Zlz&index=1 ------- Our previous show is here: "When Bad News Spells Opportunity" https://www.youtube.com/watch?v=iEgjm3cLQEI&list=PLVT8LcWPeAugpcGzM8hHyEP11lE87RYPe&index=2&t=14s -------- Articles mentioned in this report: "Oil Price Inflation & Interest Rates. What Is The Link?" https://realinvestmentadvice.com/oil-price-inflation-interest-rates-what-is-the-link/ ------- Get more info & commentary: https://realinvestmentadvice.com/newsletter/ -------- SUBSCRIBE to The Real Investment Show here: http://www.youtube.com/c/TheRealInvestmentShow -------- Register for our next Candid Coffee: https://us06web.zoom.us/webinar/register/3016835714744/WN_zCk25t5QThq7CG5NHH4UIg ------- Visit our Site: https://www.realinvestmentadvice.com Contact Us: 1-855-RIA-PLAN -------- Subscribe to SimpleVisor: https://www.simplevisor.com/register-new -------- Connect with us on social: https://twitter.com/RealInvAdvice https://twitter.com/LanceRoberts https://www.facebook.com/RealInvestmentAdvice/ https://www.linkedin.com/in/realinvestmentadvice/ #InvestingAdvice #Apple #CPI #Inflation #MortageRates #AffordableHousing #DownPayment #HomeOwnership #Markets #Money #Investing

(9/13/23) Markets rallied into Apple's iPhone reveal, then sold off yesterday; who can afford an iPhone 15? CPI for August to be released this morning (3.7% vs anticipated 3.6%). Lenders are now rolling out a 1% down payment program in hopes of reviving their business. The thing about home ownership: It's always something. How do mortgage lenders do it? They eat part of the rate up front, but YOU will pay for it on the back end. What does a larger (20%) down payment say about financial ability? The cost of home ownership goes beyond being able to afford a mortgage payment; home prices are a function of supply & demand.  No one wants to sell into a housing market with 7% mortgage rates. The tricks home builders use; How "good" do Baby Boomers have it (and why)? Time to invest, bull markets; thought processes about money, managing expenses. What is an IPOP all about: It's NOT selling at a discount. (Fiscal responsibility doesn't sell products) What do 20% of Gen-Z's want to be? Social Media influencers. Switching from spending to saving mode. SEG-1: The Apple Reveal: Who Can Afford an iPhone? SEG-2: Is the 1% Down Payment a Win-win? SEG-3: The Cost of Home Ownership: Why Prices are Too High SEG-4: Why Baby Boomers have it So "Good" Hosted by RIA Advisors Chief Investment Strategist Lance Roberts, CIO, w Senior Financial Advisor Danny Ratliff, CFP Produced by Brent Clanton, Executive Producer -------- Watch today's show on our YouTube channel:   -------- The latest installment of our new feature, Before the Bell, "Rising Bottoms & Declining Tops" is here:  https://www.youtube.com/watch?v=DK_yt7qpT20&list=PLwNgo56zE4RAbkqxgdj-8GOvjZTp9_Zlz&index=1 ------- Our previous show is here: "When Bad News Spells Opportunity" https://www.youtube.com/watch?v=iEgjm3cLQEI&list=PLVT8LcWPeAugpcGzM8hHyEP11lE87RYPe&index=2&t=14s -------- Articles mentioned in this report: "Oil Price Inflation & Interest Rates. What Is The Link?" https://realinvestmentadvice.com/oil-price-inflation-interest-rates-what-is-the-link/ ------- Get more info & commentary:  https://realinvestmentadvice.com/newsletter/ -------- SUBSCRIBE to The Real Investment Show here: http://www.youtube.com/c/TheRealInvestmentShow -------- Register for our next Candid Coffee: https://us06web.zoom.us/webinar/register/3016835714744/WN_zCk25t5QThq7CG5NHH4UIg ------- Visit our Site: https://www.realinvestmentadvice.com Contact Us: 1-855-RIA-PLAN -------- Subscribe to SimpleVisor: https://www.simplevisor.com/register-new -------- Connect with us on social: https://twitter.com/RealInvAdvice https://twitter.com/LanceRoberts https://www.facebook.com/RealInvestmentAdvice/ https://www.linkedin.com/in/realinvestmentadvice/ #InvestingAdvice #Apple #CPI #Inflation #MortageRates #AffordableHousing #DownPayment #HomeOwnership #Markets #Money #Investing

El Ayuntamiento de Rincón de la Victoria ha presentado hoy el cartel y programación de la Feria de Torre de Benagalbón que se celebrará de 27 al 30 de julio. El alcalde, Francisco Salado (PP), junto a la concejala de Ferias y Fiestas, Mari Paz Couto (PP), el presidente de la Asociación de Vecinos Torresol, Antonio Pérez, y miembros del colectivo ha dado a conocer las actividades que se desarrollarán durante estos días, “en un enclave inigualable a pocos metros del mar, en la explanada de la antigua Estación de Ferrocarril, donde celebramos una de las ferias más familiares del municipio, de las más acogedoras, que disfrutan vecinos y vecinas, visitantes y turistas”. Salado ha tenido palabras de agradecimiento y felicitación hacía la Asociación de Vecinos Torresol, y su junta directiva, “por su 45 aniversario de historia, actividades, y tradiciones que han transmitido generación tras generación”. Por su parte, la edil ha explicado que “este año viviremos una feria con actividades para todas las edades, con especial interés en mantener las tradiciones, la buena gastronomía y música en directo todas las noches”. El presidente de la Asociación Torresol, Antonio Pérez, ha agradecido la colaboración y apoyo del Ayuntamiento “que es indispensable para la realización de estas fiestas, así como a comerciantes, vecinos y la labor de los miembros de la asociación, hombres y mujeres, que trabajan durante todo el año para que estas fiestas se celebren con el mejor ambiente”. Las fiestas comenzarán el jueves 27 de julio con el almuerzo homenaje a la 3º edad. Durante la tarde habrá actividades infantiles. A las 22:00 horas se celebrará la elección de Mises, que dará paso a la actuación del grupo flamenco `A compás´. Esta jornada se dedicará al Día del Niño con precios especiales en las atracciones. El inicio de las fiestas del viernes lo marcará el pregón a las 22:00 horas a cargo de Eduardo Rando Montañez, vecino de Torre de Benagalbón. La noche continuará con la orquesta `El Tumbao ´ y el grupo `DLOCOS´ Tributo al Canto del Loco. Durante la jornada del sábado se celebrarán actividades deportivas y de grupos de baile de la Asociación Torresol. La noche será musical con la orquesta `El Tumbao ´ y el show musical de `QGAIN´. La última jornada de la feria acogerá la típica degustación de paella popular de la feria a las 15.00 horas, y la tradicional misa rociera que se celebrará a las 19.00 horas con la actuación de `Aires Marineros´ en la iglesia del CEIP La Marina. La música de `IPOP´, y los DJ `SAU DJ´ cerrarán las fiestas de este año. La autora del cartel de este año es Ana Peinado, quien también ha sido la encargada de repasar la programación en la rueda de prensa.

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas.👂 Han sonado: 01 PJ Harvey - A Child's Question, August 02 Jayla Kai - See Someone 03 PawPaw Rod - Is It Magic? 04 Baxter Dury; JGrrey - Aylesbury Boy 05 Kae Tempest - Love Harder 06 Killer Mike; Eryn Allen Kane - MOTHERLESS - Single Version 07 Rahill; Beck - Fables 08 Nabihah Iqbal - Dreamer 09 Indigo De Souza - You Can Be Mean 10 The Family Battenberg - Feed Yer (Nganga) 11 Noah and the Loners - Protest Anger 12 Young Fathers - Rice 13 Noel Gallagher's High Flying Birds - Council Skies 14 Bully - Hard to Love 15 Madeline Kenney - Superficial Conversation 16 Decisive Pink; Kate NV; Deradoorian - Dopamine 17 Mandy, Indiana - Drag [Crashed]

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas.👂 Han sonado: 01 Mounika.; Ural Thomas and the Pain - I Looked into Her Eyes 02 Lot D - Midtown Tempo 03 HARD FEELINGS; Rye Rye - Dangerous - Remix 04 yunè pinku - Sports 05 Nia Archives - Sunrise Bang Ur Head Against Tha Wall 06 ZUSO - Higher 07 Burland; Zongo Abongo - Telephone No Wire 08 Two Shell - love him 09 The Jungle Giants - Trippin Up 10 1tbsp - It's Very Loud 11 Mick Jeets - Yummy 12 Fred again..; Skrillex; Four Tet - Baby again.. 13 Ian DPM - One For The Waltzers 14 LUZ1E - Sensitivity ft. DALO 15 Narciss; Estella Boersma - Ocelot - Estella Boersma Remix 16 Tower Block Dreams - YesLDN

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas.👂 Han sonado: 01 Lonnie Holley - I’m a part of the wonder 02 Getdown Services - Cream on the crop 03 Heartworms - Consistent Dedication 04 Feist - Borrow trouble 05 Nemahsis - I wanna be your right hand 06 Steve Mason, Javed Bashir - Brixton fish fry 07 Fontaines D.C. - Cello Song 08 Maxime - Cherry Stems 09 Sleaford Mods feat. Perry Farrell - So trendy 10 Sllow - Dye-Dye 11 Sam Austins - Keep you company 12 Pine Barons - Frantic Francis 13 Fight like apes - Pretty Keen On Centrefolds 14 Monolink - Running 15 Kerala Dust - Moonbeam

Sobran las palabras para describir que es Radio Curie: Música y más música escogida selectamente por eclectic_club. El programa se emite quincenalmente en iPop a las 20 horas.👂 Han sonado: 1 Barley - Water From Your Eyes 2 Orbital feat. Penelope Isles - Are you alive? 3 Kelela - Contact 4 Róisín Murphy - Coocool 5 Yves Tumor - Echolalia 6 Afflecks Palace - Holidays 7 Alizzz - Superficial 8 Caroline Polachek - Welcome To My Island 9 Beck - Thinking about you 10 Kali Uchis - Moonlight 11 Wednesday - Chosen To Deserve 12 Isle of Wight Coach Party - Micro Aggression 13 Baba Ali - Burn me out 14 Patrick Wolf - Nowhere game 15 Mozart Estate - Relative Poverty

We had the pleasure of interviewing Sofia Treadway over Zoom video!At just 17 years old, the bilingual singer-songwriter Sophia Treadway is taking the music industry by storm with her latest single, Kiss N Tell, produced by 2022 Grammy-Award Winner (Best Album, Jon Batiste) Autumn Rowe! The singles sound is a nod to the late 90's/early 2000's and will give nostalgic vibes to those who remember that era of music well! The Dallas-based singer is well known for her latest single, Close to Me, and her other popular songs, I'm Good (2021), Not That into You (2020), Beside Me (2019), and Can't Stop Thinking About You (2018). Born in Greenville, South Carolina, Sophia has always wanted to share her love of singing with the world. Sophia made her journey to Memphis, Tennessee from California at the age of 5 where she auditioned for her first show. After blowing the judges away with her performance of Adele's "Rolling In The Deep" she began working with infamous vocal instructor, Bob Westbrook, former teacher to Justin Timberlake, Britney Spears Lance Bass, Chris Young, Lucy Hale, Olivia Holt, Peyton List and many more! Sophia took her singing career to the next level with her performance in 2013 at various events including the Delta Fair. By 2014, Sophia won in the national competition, IPOP, and in 2017 found herself in the main showcase at the Mike Beaty Model & Talent Expo in Dallas, TX. After her many accomplishments as a young singer, she launched her path to creating original music with the support of Platinum Record music producer Marc Williams of Indasoul Entertainment, and Sony/ATV music producer Christopher 'C-Ray' Roberts of OnKey Entertainment! Additionally, she has been mentored by 2022 Grammy-Award Winner Autumn Rowe (Best Album for ‘We Are' with Jon Batiste) for the last 6 years, who has worked alongside Sophia homing in on her writing skills and sound.Sophia feels passionate about both her Latina and American heritage and is striving to incorporate both languages into her music. She also feels strongly about including her personal experiences in her music to connect with her audience. Her hit single, Beside Me, was written to encourage her fans to feel empowered and always express their individuality! Sophia is an avid supporter of the Thirst for Life project- an organization that builds wells in Africa for people who do not have access to clean water. In addition to the Thirst For Life project, Sophia loves to perform and has gone on to sing the national anthem for the Memphis Grizzlies and the Memphis Redbirds!We want to hear from you! Please email Tera@BringinitBackwards.com. www.BringinitBackwards.comThis episode is sponsored by American Musical Supply. Go to https://ter.li/AmericanMusicalSupply-BACKWARD and use promo code BACKWARD to receive $20 off a purchase over $100.#podcast #interview #bringinbackpod #SofiaTreadway #KissNTell #NewMusic #zoomListen & Subscribe to BiB https://www.bringinitbackwards.com/follow/ Follow our podcast on Instagram and Twitter! https://www.facebook.com/groups/bringinbackpod

A seven-year-old Londoner will be travelling to Los Angeles this July, to perform in the International presentation of performers also known as iPOP! Lorkin and his mom, Anthea, join Mike Stubbs to talk about the upcoming event and how it all came to be. See omnystudio.com/listener for privacy information.

They say that anyone can answer a question but it takes smarts to ask the right question. And while it is true, questions and answers cannot be seen in siloes. They are always connected for obvious reasons. But more importantly, it is not just a question that needs smarts, but also an answer that needs intelligence. While a long-winded response is not a preferred answer, a concisely given incorrect answer is equally useless. So, what is Answer Intelligence (AQ), and how to develop it? I am talking with Brian Glibkowski in this episode to discuss more on it.In this episode, we are talking about:What is more important - asking the right question or answering appropriately?What makes or breaks an answer?Importance of recognizing what is being asked.How can one understand context?How to handle situations when you don't have a context?Origin of AQ (Answer Intelligence) framework.The six high AQ practices.Problems with overdoing only one aspect and how to avoid them?How AQ applies in a group setting?How does it help listeners?More resources to learn about AQ and practice.Dr. Brian Glibkowski is passionate about the role of questions and answers in business and society. Brian is an internationally recognized scholar. He is a recipient of the Emerald Citation of Excellence Award. His academic article was selected as one of the top 50 globally from 15,000 management articles in 300 peer-reviewed publications worldwide. His research on the six WH-questions (what, why when, where, who, how) as the Association of Human Resource Development recognized a common framework for communication and decision-making as one of ten articles that will shape the 21st century. He is a pioneer of a new science of answers called Answer Intelligence (AQ)™.  He is the author of the book Answer Intelligence: Raise Your AQ (2021). Through AQ certification and associated assessments and tools, AQ is used by certified partners in the USA, UK, UAE, India, and Australia to benefit forward-thinking organizations worldwide.Dr. Glibkowski is a Professor and CEO of Semplar Science, the company established to commercialize his research. Learn more at www.RaiseYourAQ.com.ABOUTICT Podcast is all about innovation, communication, and technology – a few key areas that are super important in today's world. If you want to know what it takes to be a better innovator, better communicator, and leverage technology to make this world a better place, please subscribe. Every week, I bring new perspectives, ideas, tips, and techniques so that you can improve all these aspects of your life. WEB: https://www.anandtamboli.comLINKEDIN: https://www.anandtamboli.com/linkedinYOUTUBE: https://www.anandtamboli.com/youtubeBOOKS: https://www.anandtamboli.com/amazonSupport the show (https://www.anandtamboli.com/author?s=podcast)

La radio y la música de iPOP en la calle. El 23 de Octubre estuvimos en la calle poniendo música a una inauguración de la exposición "La Nueva Disquera" de Miguel Bustos. También estaba la tienda Cosmic Records Store, capitaneada por Àlex Gasulla responsable de La Càpsula RadioShow Podéis disfrutar de: POPLAROID y su muestra de indie nacional, Pau Llop del colectivo Naltros Sols con sus oldies but goldies variados, Adrián Zarco de FUEGO EN LA PISTA DE BAILE punk reggae y soul, y para finalizar Jordi de MINERAL con la dosis de indie internacional y nacional #laradioNOradio #laradioSINalgoritmos

New membership community!

We're back for season 2! For our first episode of the season, we're hearing from Dr. Michael Snyder. He is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine at Stanford University. Mike received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and multiomics. His lab was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. He launched the field of personalized medicine by combining different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person, and his laboratory pioneered the use of wearables technologies (smart watches and continuous glucose monitoring) for precision health. He is a cofounder of many biotechnology companies, including Personalis, SensOmics, Qbio, January, Protos, Oralome, Mirvie and Filtricine. In this episode, we talk about how Mike got started doing research, why he transitioned to doing more translational research, what some of the differences are between working in academia, start-ups, and pharma, and how the skills you learn as a scientist can be helpful no matter what career you choose. Get in touch with Mike and the Snyder Lab research: Twitter Lab Website: https://med.stanford.edu/snyderlab.html Enroll in the COVID wearables study Enroll in other Snyder Lab studies Get in touch with Steph: Instagram Twitter Get in touch with the podcast: Email: rootstostempodcast@gmail.com Website: rootstostempodcast.com

In a companion interview to his June 7 talk with Stanford's Michael Snyder, Harry speaks this week with Noosheen Hashemi, who—with Snyder—co-founded the personalized health startup January.ai in 2017. The company focuses on helping users understand how their bodies respond to different foods and activities, so they can make diet and exercise choices that help them avoid unhealthy spikes in blood glucose levels.January's smartphone app collects blood glucose levels from disposable devices called continuous glucose monitors (CGMs), as well as heart rate data from patients' Fitbits or Apple Watches. The app also makes it easier for users to log the food they eat, and see what impact each food has on their glucose levels. Once the app has enough data, January's machine learning algorithms can start predicting the effects of different foods and activities on blood glucose. It can then recommend meals and exercise that'll help users keep their blood glucose in a healthy target range. The goal isn't to prevent glucose spikes completely, but rather to prevent diabetes from emerging over the long term in people at risk for a cluster of serious conditions known metabolic syndrome. That could help individuals live longer, healthier lives. And at a population level it could save billions in healthcare costs.Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:• Launch the “Podcasts” app on your device. If you can't find this app, swipe all the way to the left on your home screen until you're on the Search page. Tap the search field at the top and type in “Podcasts.” Apple's Podcasts app should show up in the search results.• Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.• Type MoneyBall Medicine into the search field and press the Search button.• In the search results, click on the MoneyBall Medicine logo.• On the next page, scroll down until you see the Ratings & Reviews section. Below that, you'll see five purple stars.• Tap the stars to rate the show.• Scroll down a little farther. You'll see a purple link saying “Write a Review.”• On the next screen, you'll see the stars again. You can tap them to leave a rating if you haven't already.• In the Title field, type a summary for your review.• In the Review field, type your review.• When you're finished, click Send.• That's it, you're done. Thanks!Full TranscriptHarry Glorikian: I'm Harry Glorikian, and this is MoneyBall Medicine, the interview podcast where we meet researchers, entrepreneurs, and physicians who are using the power of data to improve patient health and make healthcare delivery more efficient. You can think of each episode as a new chapter in the never-ending audio version of my 2017 book, “MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market.” If you like the show, please do us a favor and leave a rating and review at Apple Podcasts.Harry Glorikian: I've been making the show long enough that you can see a kind of family tree emerging, with branches that connect many of our episodes.That's definitely the case with today's interview with Noosheen Hashemi, the co-founder and CEO of the precision health company January AI.The branch leading to Hashemi started back in June of 2021 when I interviewed Professor Michael Snyder, the chair of Stanford's Department of Genetics.Snyder is a huge proponent of using wearable devices to help people make better decisions about their own health. In fact, the day we spoke he was wearing seven separate devices, including one called a continuous glucose monitor or CGM.A CGM is standard equipment these days for about 3.5 million diabetics in the U.S. who need to know when their blood sugar is too high and when it's time to take more insulin. But Snyder believes that blood glucose data could also help tens of millions of other people who don't yet take insulin but may be on their way to developing full-blown diabetes.Back in 2016 Snyder got a visit from Hashemi. She's a longtime Silicon Valley tech executive and philanthropist who'd been searching for a way to use AI, wearable devices, and big data to get more people involved in medical research. Hashemi told me it took just two meetings for her and Snyder to decide to join forces to co-found January. The company makes a smartphone app that collects blood glucose data from disposable CGMs, as well as heart rate data from patients' existing wearable devices such as their Fitbit or Apple Watch. The app also makes it easier for users to log the food they eat, and see what impact each food has on their glucose levels. Once the app has enough data, January's machine learning algorithms can start predicting the effects of different foods and activities on blood glucose. It can then recommend meals and exercise that'll help users keep their blood glucose in a healthy target range. The goal isn't to prevent glucose spikes completely, but rather to prevent diabetes from emerging over the long term in people at risk for a cluster of serious conditions known metabolic syndrome. That could help individuals live longer, healthier lives. And at a population level it could save billions in healthcare costs.As you're about to hear, Hashemi and I talked about why glucose monitoring is so important and what companies like January can do in the future to make the predictive power of AI available to more people.Harry Glorikian: Noosheen, welcome to the show. Noosheen Hashemi: Thank you, Harry. Harry Glorikian: So, it's great to have you on the show. It was interesting that, you know, the minute Dr. Snyder mentioned the company, I was immediately Googling it. And I was like, oh, I have to talk to this company. I have to understand what they're doing and, and what's going on.And to be quite honest, I've been doing my homework for the past couple of weeks. And I'm like: I think I have to call my doctor and get a ‘script to actually use the product. Just to help everybody get up to speed on this, can you bring people up to speed on where we are with glucose monitoring and health in general? Whether they have diabetes or whether they're just, you know, what, I, maybe someone like me who I hope is a generally a healthy person.Noosheen Hashemi: Sure, absolutely.  Yeah. So from Mike Snyder's four-year multi-omic IPOP research,  we learned that people who are so-called healthy and have healthy A1C levels could actually have huge glycemic variability. He sometimes calls these people with pre pre-diabetes.  I think eight people developed diabetes during his four-year study.There haven't been enough longitudinal studies in healthy people with glycemic variability to suggest that they will necessarily develop diabetes. So to date, there's really no conclusive evidence that healthy people can benefit from balancing their blood sugar. Also, not all sugar spikes are bad and a two-hour bike ride might produce a big spike, but that's fine. It's not the spike by itself that we worry about. It's really  how high the spike is against our baseline, against the population, whether the spike comes down quickly, the shape of the curve, the area under the curve. These are the things that are illuminating in terms of our state of metabolic health.So  at January we really view metabolic health as a spectrum. So we want to support people to figure out kind of where they are on that spectrum. And to try to really help them move up to healthier points on that spectrum. So we don't see it as a moment in time where you are something or you are not something. You are kind of on a spectrum of metabolic health, and we continuously want you to be self-aware and, and really improve your location on that spectrum. Now, something to keep in mind,  and why I think it's important for people to take action on this, is that 84% of the 88 million people believed to have pre-diabetes today, and 22% of the 34 million people that are believed to have diabetes today, are not diagnosed. They are undiagnosed. That's 75 million people walking around with pre-diabetes and don't even know. So, if we don't measure people's health, that doesn't mean they're healthy.  So we really encourage people to be  you know, vigilant with their health learn so that they can, they can act, you know, self-advocate. Be able to self-manage.So we do think that wearables are an easy, useful way to kind of see where things are, but then you need companies like January to make sense of it all. Harry Glorikian: Yeah. I mean  you know, it's interesting because you know, I'll go to my doctor and they'll do that one time measurement. It's like taking your car in and you're like, it was making a noise. It's not making the noise right now, but, you know, try and diagnose when that event is not happening. Whereas with the wearables, I can, I can actually see, you know, my, my heart rate variability change depending on my exercise process. I can see my sleep change if I had one too many glasses of wine. I have to tell you, I hate it because I would like to have more wine than my monitor allows me to have, but you know, you see the immediate feedback, which would let you sort of course-adjust accordingly. And you know, when I, there was a paper, I believe that was published in Israel where there, I think it was 500 people that they looked at and where you could see that every person, they could eat the same foods, but their spikes would be different or how long that spike would be based on genetics, based on their microbiome. And so if you're not monitoring, how will you know that your quote, healthy diet is actually healthy for you? Noosheen Hashemi: You don't.  You definitely don't. And yes, that's study shows variability between people, but also we've shown glycemic variability for the same person. So we had somebody at the office have the same good sleep nine days in a row, and they had a different glycemic response to that. Mostly every single day, nine days in a row, depending on how much they had slept, how stressed they were, how much workout they had done. And most importantly, how much fiber was in there.  So we are radically different person to person, and this is why we encourage people.  No one is going to know you as well as you do. And no one's going to be as interested in your health as you are  as you should be, as you might be. So we really encourage people to learn, learn, be self-aware self-advocate, self-educate. Harry Glorikian: So, help people understand this term metabolic syndrome, you know, and, and talk about how many people, maybe who are pre-diabetic go to full-blown diabetes, you know? Noosheen Hashemi: Okay. Yeah. So  I mentioned that 122 million people have either diabetes or pre-diabetes in America.  88 million plus 34 [million]. And then a larger number of people, if you believe Mike Snyder's pre-diabetes number, that's even a larger number. But metabolic syndrome is a cluster of conditions that leads to type 2 diabetes, heart disease, and stroke. These conditions are basically high blood sugar—which has been historically measured by A1C  blood tests called hemoglobin A1C, but increasingly it's measured by time and range using a CGM—high cholesterol and triglyceride levels, high blood pressure, high BMI, and high waist to hip ratio. So this kind of fat right in the middle.So the 2002 diabetes prevention study showed that unless there's an intervention, 58% of the people that have pre-diabetes could end up with diabetes. And usually they think of this prevention as weight loss.That's what the DPP programs, diabetes prevention programs, are about.So if you have pre-diabetes the cells in your body don't respond normally to insulin. And insulin is a hormone that facilitates your cells taking up glucose, which is a source of energy for your body. Your pancreas basically makes more insulin to try to get the cells to take up glucose. You sort of get into this terrible vicious circle. So eventually your pancreas can't keep up and then you have this sort of excess sugar sitting in your bloodstream, which is really a problem. And it can really lead to microvascular complications like retinopathy or neuropathy or diabetic nephropathy.So as you know, diabetic retinopathy is the most common cause of blindness in working adults in the developed world. And in diabetic neuropathy, essentially high blood sugar can injure nerves throughout the body. And usually damages nerves in the feet, in the legs and feet, which hear about foot ulcers and amputations coming from this.And of course  diabetic kidney disease. Nephropathy is something that  is the number one cause of kidney failure, actually. Almost a third of people with diabetes develop kidney disease. So you add this with the high blood pressure we can increase the force of blood through your arteries and damage arteries. And then you have excess blood pressure, you knowblood pressure and diabetes together, basically increase your risk for heart disease. So it's really a terrible cluster of conditions to have. And so if you have three of these conditions, three of these five, you essentially have metabolic syndrome. And if you have metabolic syndrome, you're at a higher risk of developing these different diseases. You really don't want to go down this path. The path itself is not great. And then the comorbidities from this path are just worse and complications of course are very painful, costly, and potentially, deadly.Harry Glorikian: And so that's one end of the spectrum, but in reality, even someone like me who tries to watch he eats, who goes running regularly, or tries to go running regularly. I mean, you know, I have sleep apnea because they tell me my BMI is too high. Right. So  but this sort of technology, you know, I could be spiking and keeping a high glucose level, which would inhibit my ability to lose weight, et cetera. So how can more data about blood glucose, and its relationship to diet, help people avoid diabetes?Noosheen Hashemi: Yeah. So for so long, we've been able, we've been told just to avoid refined sugar, refined flour, eat a lot of vegetables, walk 10,000 steps. You'll be fine. Or, you know, weight loss is given as the end goal to cure all diseases. You know, why don't you, Harry, drop 25 pounds? Or how about drop 5 to 10% of your weight? Harry Glorikian: Just like that!Noosheen Hashemi: It's true, weight loss really improves biomarkers. But how many people who get this advice can actually do that? And at the timeframe that they need to. So we feel like that's just not a practical approach to solving a problem.A more practical approach is to really figure out what works for each individual. You know, you mentioned you've dialed your own wine drinking based on its impact. I've done the same. I was, you know, enjoying two, three sips of wine. And then I learned that it would wake me up in the middle of the night. So I stopped having even the two, three sips of wine. So don't feel bad that you can't have your second and third and fourth glass. But basically we offer a multitude of levers that you can dial for your lifestyle. For example, intermittent fasting and calorie restriction together have shown benefits in clinical studies for improving insulin sensitivity, if you do them together. So you can't just fast and then gorge yourself. But if you fast and you restrict your calories together, you can really improve insulin sensitivity. So we let you, we help you using the January program to learn to experiment with fasting and calorie restriction and figure out what works for you. How much of it you can make. You know, slowly  help you essentially build it into your habits and your daily routines to fast. You know, we increase your fasting period 15 minutes at a time. So you may start with January you're eating 16 hours a day and you're fasting eight hours. You may end the program having reversed that.And other thing is we, we really pro promote fiber consumption. So increased fiber intake has been associated with higher levels of bacteria-derived short chain fatty acids, which is a regulator of GLP-1 production. As you know, GLP-1 is an incretin and a recognized regulator of glycemic homeostasis and satiety. So we help you track how much fiber you're eating. We encourage you to eat more, knowing what foods spike you, spike your blood sugar, helps you basically eliminate or reduce consumption of those foods. It tells you how much, how much of those things to eat  or alternatives that kind of honor your food preferences  and food tastes, but have lower glycemic index. If you can't walk 10,000 steps a day, okay. January tells you how much you need to walk, when you need to walk to keep your blood sugar in a healthy range. So you really need data  to, to dial your lifestyle. There are many levers and there are no silver bullets and there's too much to keep in your head. Which is why it's nice to have AI sort of help you kind of make, you know, take it all in to a platform and then synthesize it and give you insights.Harry Glorikian: Yeah. I mean, like,  I've got my, my Apple Watch. I've got my, you know, Whoop band. Right.I don't have as many as he [Mike Snyder] does, but  I know, I think my wife would kill me if I, if I was wearing eight things, but, but it's, you know, it's true. Like it's, you know, each one of these, because they're not holistically designed, give me a different piece of data that then I can then react to. You know, one is probably more of a coach that causes me to push a little bit farther, you know, et cetera. So  I mean, I hope one day we evolve to something that's a little bit more holistic so that the average person can sort of, it becomes more digestible and more actionable. But you know, I do believe, based on my conversation with him and even all the work that I do multi-factorial biomarkers or multi biomarkers are going to be how you manage, you know, yourself much better.But you know, tell me how January started. What is the thing that excited you about what you saw and what attracted you to this role? Noosheen Hashemi: Yes, absolutely. So January's origin story started with me deciding in 2016 to start my own company, essentially, after many years of running a family office, investing in, serving on boards of companies and nonprofits.  I had early success at Oracle  where I rose basically from the bottom of the organization in 1985 to vice-president by age 27. Along [with] Mark Benioff, who at the time was 26. It was quite the time, taking the company from $25 million to $3 billion in revenue. So  you know  a really, really amazing tenure there. In 2016, I started this massive research in, into theses that were getting a lot of attention, you know, big trends over the next decade. And most importantly, what I really knew. You know, the classic kind of [inaudible].  I happened to attend a conference, a White House Stanford University conference on societal benefits of AI and how to integrate sort of ever-changing AI into everyday life and into the real world. It was a healthcare panel that took my breath away. So Faith A. Lee who had organized the conference with Russ Goldman. They suggested that interested parties run off to this machine learning and healthcare conference in LA two weeks. I immediately booked my ticket. And there I met Larry Smarr. I don't know if you've come across him or not, but he was the first quantified self, maniacal quantified self person I had come across. And he had diagnosed his own Crohn's disease way before symptoms had manifested. And so, and then the common theme of this conference, between all of these presentations was that machine learning could essentially fill in for missing variables in research, not just going forward, but going backwards. So I was just hooked and I never looked back.But it was a hard problem. My own husband had been investing in healthcare and warned of like an opaque sector. He was like, “Honey, this is heavily regulated incentives are aligned with acute disease, not with chronic disease, not to mention even anything or prevention. It's just not a market economy.” And he knew how interested I am in market economies. My first love before medicine was economics. So that's a whole different podcast. So he warned that I'd be sort of fighting this uphill battle, but I was not discouraged. I basically kept on researching.I came across the MIT economist Andrew Lo. I don't know if you've come across him, but you should definitely talk to him. He's brilliant. His work showed that so little research had been done compared to what we really need to do in terms of medical research. And he comes up with ways of funding, medical research, he has a lot of innovative ways that we could really change  the whole model of medical and scientific research, but it kind of became obvious to me that the answer was that we needed to get everyone involved in research.So just, just putting things in perspective. After Nixon declared a war on cancer 50 years ago, we now have some therapeutics and some solutions to cancer. We have really nothing for neurological diseases. We're spending over $300 billion just on symptoms of Alzheimer's— don't talk about even the cure or anything like that. We have nothing for aging, which is the ultimate killer. So it was, to me, the answer was obvious, which was, we have to get everyone contributing to research. Everyone should be looking at themselves. And then with the data, we can also learn across populations. And so deep phenotyping of the population sort of in a multi-omic way was the answer.And that's what led me to Mike Snyder. I actually looked for multi-omics. I went to Stanford medical school and I met with the CEO. He said, what are you interested in? I said I'm interested in multi-omics. He said, you have to talk to Mike Snyder. And so  basically what Larry Smarr had done at the [San Diego Supercomputer Center] was to measure everything by himself. But Mike had essentially extended this kind of research to others, not just to himself. So not only sort of diagnosed himself with diabetes before the doctors, but he'd also run the Human Microbiome Project, the IPOP study, innumerable other research using metabolomics, proteomics, transcriptomics, wearables, and so on.So he had spent a lifetime studying how people went from healthy to disease essentially. And he had taken a whole person approach, which is what I was interested in.  And so in his role as chairman of genetics at Stanford and head of precision medicine at Stanford, he was kind of already living in the future. And that's kind of where I thought, you know, all of us needed to go. So our first meeting was supposed to take 45 minutes. It took 90 minutes. And in our second meeting, we agreed to join forces. It was like, it was instant.  It was just instant chemistry. Like the universe just brought us together.And then all of a sudden sort of everything fell into place for me. Looking back at my life, I been getting ready for this actually all along. Caring for my dad who had been diagnosed with cancer too late to actually give him  a surviving chance. My mom  had been misdiagnosed with asthma when she had heart failure. So I had to leave my family, you know, everyone get together and really intervene. Really changed her, her lifestyle in order to save her life. She is thankfully now 91 years old and living fine, but it has absolutely no salt in her life and a completely different, different life. My own health, my own health journey sitting in front of a computer for three decades, more than three decades, as we know that now they call it called sitting, you know, Harry Glorikian: Right, the new smoking. Noosheen Hashemi: The new smoking. My experience running a couple of hardware companies, my love of food, and my skills of kind of scaling companies. You know, all of this came together. I just basically became obsessed with prevention and I felt that, you know, food could play an outsized role.So wearables, you know, give you signals from the body continuously, which is incredible.  But you also need to understand what people are eating and, you know, we can talk about that a little bit later, but we can basically now imagine predicting chronic conditions, much like Larry and Mike had. And then, you know, postponing and potentially preventing them. And if they've already started, prevent them. Harry Glorikian: Yeah, I was lucky enough to be there and help when Evidation Health was getting off the ground and, you know, once we started to see the data coming in, I remember looking at the data. Is that real, like, is that actually happening? And I was like, the first thing I was thinking of was like, how do we design a clinical trial? Like if you're going to actually say that's happening, that trial is not going to be trivial to set up, to make that claim, but you could see it in the data.And, you know  I actually think some of the shifts that you're talking about, if it wasn't for things like the Affordable Care Act, if it wasn't for putting EMRs in place, if it wasn't for some of these shifts that have happened, you and I would still be, you know, battling this system that pays you no matter what. Right? And I think now is technology is a way that that can empower the average person to manage their own health. I'm not going to say optimally, but boy, a hell of a lot better than no information. I mean, at least some information can maybe give you an early warning light of something that you might be able to intervene in.And I don't know anybody that likes being sick. I mean, I don't do well when this thing starts to age a little bit and not function the way that I want it to. So I've tried to try and keep it in as good of a running condition as I can. So it lasts as long as possible. I mean, I'm one of those people that would listen if I just drop dead at 95, like just boom gone. I would be so happy. Right. As opposed to this sort of chronic  dynamic. [musical transition]Harry Glorikian: I want to pause the conversation for a minute to make a quick request. If you're a fan of MoneyBall Medicine, you know that we've published dozens of interviews with leading scientists and entrepreneurs exploring the boundaries of data-driven healthcare and research. And you can listen to all of those episodes for free at Apple Podcasts, or at my website glorikian.com, or wherever you get your podcasts.There's one small thing you can do in return, and that's to leave a rating and a review of the show on Apple Podcasts. It's one of the best ways to help other listeners find and follow the show.If you've never posted a review or a rating, it's easy. All you have to do is open the Apple Podcasts app on your smartphone, search for MoneyBall Medicine, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but it'll help us out immensely. Thank you! And now back to the show.[musical transition]So you mentioned AI, you mentioned machine learning. Where do machine learning and other forms of AI fit into January's service and you know, what do you do on consumer data? What kind of predictions can you make that wouldn't otherwise be possible?Noosheen Hashemi: Okay. I can first talk about exactly that. What did we do that hadn't been done before. What is really unique? What are we filling? So essentially in one word, it is prediction. You said it. So  as you know, there've been, there have been glycemic prediction models for type 1 diabetes, but type 1, as, you know, is a serious condition, which, you know, precision really matters for type one. It's life and death.But there hasn't been much done with type 2 diabetes. And so we set out to do predictions, for type 2 diabetes. And  the type 1 diabetes models are pretty simple. They basically are an insulin-carb calculus, essentially. But as we dug in, we realized that  you know, carbs are not all the same and that there are so many other factors besides carbs that affect glycemic response, including things like fiber fat and protein, water, and foods. We wanted to understand glycemic index and glycemic load of foods. So our major  machine learning  research projects, we basically did research for two and a half years before we sold anything.  One of the first things that we did was to try to understand the foods themselves. So we essentially built the largest database. Essentially we licensed all the, these curated food databases, and then we labeled the foods that didn't have food labels, because right now the only food labeling you really have is like grocery foods and chain restaurants.So we labeled foods and then, recognizing that glycemic response was better associated with glycemic index than carbs alone, we set out to create glycemic index and glycemic load for all these foods. Then we ran a clinical trial and associated people's glycemic response to the glycemic load of foods they were eating. And then we turned that into a prediction. So, the prediction model.  Why is it so cool? Well, why should you use your body to figure out how many glasses of wine is going to spike you? Why not have the AI tell you that? Why not do that in silico?  It's this weekend, you want to cook for your wife. You want to get her the right fried chicken recipe. Well, check those out in January, check out those recipes in January. If you know what the glycemic response of, of each one of those recipes could be, it really helps you compare foods. For kind of recipes you can comparefood items in your local cafe. You want to figure out what to eat. You don't have to put them through your body to figure out how you're going to respond, put them through the AI to figure out how you're going to respond.And then in terms of, you know, how we're different. I mean, we essentially live in the future. We, we don't  we don't live in blood pricks and strips and blood glucose meters. We kind of live in the CGM, HRM (heart rate monitor) precision foodworld. We've turned food into actionable health data, which is a necessary ingredient you need if you want to understand people's glycemic response. And if you want to be able to predict it, and that is our huge innovation that nobody has. And we have quite a bit of IP around it. There are a number of things that we're using. We're using meta-learning.  We're using  neural networks. I don't know how much I should say about what we're using. Yeah. We have one paper that we've put out, which is really, really, really simple.  But we, we always talk about, what kind of papers we want to put out and how much we should put out and how much should we not put out, but essentially you can look at the people that advise the company and you can see that, you know, we have a lot of expertise around  essentially… Harry Glorikian: But Noosheen, when you're doing this right, you need to, at some point, I think you need a baseline on say me for a certain period of time before the algorithm can then respond appropriately to that. And then doesn't that potentially change over time, time you mentioned the yogurt, the meusli, right.  And how that affects. So it's constantly gotta be in a feedback learning loop.Noosheen Hashemi: Yes. Yes. And the beauty of January is that essentially you don't have to wear a CGM 365 days out of the year. We think that with AI, we allow you to wear a CGM intermittently. So maybe you want to wear it every quarter  to update our models  just to see how things are going, but you don't need to wear it all the time. You can wear it for a period of training and then basically run your simulations in silico rather than through your body. Let the AI do the work. So you definitely should wear it intermittently so we can update our, our models because people do age. People do have inflection points in their health. They get pregnant, they travel, a lot of things change, but we don't think it's necessary for healthy people to wear CGMs all year long necessarily. Harry Glorikian: So now we're talking about consumer behavior, right, for a, for a tech product like this. And if, you know, if you look at some of the data that I've read in some of these papers, you know, the potential market is significant. It's, you know, it's quite large. I mean, if I just said, you know, 15% of the people have pre-diabetic levels of glucose after eating, that would translate to like 50 million people in the United States alone. But the service depends on the CGM, the app, the external heart monitor. It's, you know, users have to be diligent about monitoring and logging food intake and activities during the introductory month. So for a quantified self junkie, I get it. They're all over this.  What's the plan for getting everybody else on to this? Noosheen Hashemi: Well, I think it's all about the user experience. And I think we have a, we have a long way to go as an industry and for us as well.As a company we have, what we imagine to be the user experience is nowhere near where we are today.I'm old enough to remember world before Starbucks. So you would see ads on TV for MJB coffee, which is something you made at home. You know, I don't know if you remember that but Starbucks created a new experience, really a place between home and work where you would stop by for coffee.And so the outrage around the, you know, $3, $4 latteat the time, do you remember that?Well, Starbucks continue to improve the experience. They added wi-fi, they had ethical coffee, they had kind of a diverse employee population. People's initial wonder and worry gave way to this, you know, gigantic global brand. And I think all of that is because of the experience that people had. I think we need to make health a positive experience. We need to—we, including January—need to make health something that people….it's going to be a little clunky in the beginning, just like the old, you know, cell phones used to be. But while we're going through this process, the companies need to work on to improve the experience and people need to be patient with the clunkiness of everything  to get us to a place where these things become much, much more pleasant to use and easier to use, and essentially AI starts reading your mind about what you were eating and what you were doing. That is going to happen. You know, I've gotten so used to my Apple Watch now that I actually love it. It actually is doing a very good job training me. Just at the right time, you know, “Come on, you still have a chance. Let's go.” You know, all the things that it's doing  I'm actually liking it. It's it's enjoyable. Because it Is coaching. And I feel like the answer for mass adoption lives in experience. We need to improve the experience dramatically. Harry Glorikian: It's interesting though, because I I'm play with a lot of these different things and I noticed that depending on how they're designed, how they're put together, it nudges me to do that much more or et cetera. I don't always listen. Human beings don't always do what they're supposed to do for their better good. But  you can see how, when the app is designed in a way to nudge someone the right in through the right mechanisms. And that's the problem, right, is trying to—not the same mechanism works on everybody. So you may have to have multiple approaches that the system tries like AB testing for a website to, to get them to do that.But so, if the average person like me wants to do something like this, obviously I have to get a ‘script from my doctor, which just drives me crazy that I can't just—because I can buy a finger-prick, right, over the counter and poke myself a thousand times and then write down these numbers to see what happens. Which seems a little clunky in my opinion. But I can't buy the CGM that does it automatically. There's gotta be some medical person saying like, we're gonna make more money off this if we do this or do that, or, or it just doesn't make any sense to me.  How do you, how does January come at the expense reimbursement or the insured part of it, or is this just out of pocket for everybody? Noosheen Hashemi: Sure. So right now  government insurance, companies, and private insurance companies cover CGMs for people that are intense insulin users. So people that prick themselves four times a day. And so that's three and a half million out of 122 million people that have pre-diabetes or diabetes. So it's a very small population. And the rest is all cash paid. And it it's really out of pocket. So we have an early access price of $288. And we, you know, we include the CGM, but you can also buy CGMs only from January. You can just, if you just want a CGM, you don't want to do anything else. You're just curious. You want an introduction to this world? You can order a CGM from January for $80 if you want to do that. So if you're one of the 12 million people that are insured by Kaiser—and Kaiser doctors will not write you a prescription, you can go to your doctor and ask them, they won't write you a prescription—come to January. We will give you a CGM. You can be introduced to the program and then, you know, take, take up January from there and experience the magic of CGMs alone. I really do think they are a magical product because they they're showing you for the first time you kind of can see inside your body, which is really phenomenal. Unfortunately by themselves, they're not that effective and they're not that effective by themselves longitudinally. So if you really want to keep track of how you've been doing, what food spiked you, how you can, you know, what kind of exercise, things like that. They don't really have that additional intelligence, but they are magical, they are really magical tools. But, you know, you want an insightful experience on top of that. With the AI that can essentially synthesize this kind of data from your heart rate, monitor from your food, from your glucose monitor and sort of let you know how much to eat, what to eat, how to hack your food, how much to walk, how much, how much to fast, when to fast, how much fiber you're having, not having. That's where we come in. Harry Glorikian: I feel like at some point I'm going to need a big monitor in my house that just tells me these things as I'm walking by. But you know, it, it's interesting. I mean, we are entering the era of real wearables and apps and big data and, and, you know, but here's the question though. Soyou know, Apple just announced what's going to be the update to their iOS and, you know, pretty soon I'm going to be able to push a button and share data with my physician.  Which is funny because I go in his office and I pull up my phone and I'm like, here's my longitudinal. And here's my longitudinal. And I'm like, look, you can take the measurement because you're supposed to, but here's how it looks over the last three months as opposed to the one time when I'm here. Can January's customers export and share the data with their doctor? Noosheen Hashemi: We have a report  midstream at 14 days that you can share  with, with your doctor. But of course we intend to, you know, we have features planned that are going to make things way more easily done, much more easily in the future. We really strongly believe that people should own their own health data. We are huge advocates for people owning their own health data, because there are a lot of people hanging onto your health data and they don't want to give it to you. I'm talking about device makers and others. You're paying for the device, which comes with the data, but they don't want you to have the data. So they're like, “You can have the data and study it yourself, but you can't give that data to other people.” But that doesn't work.We are living in a multi-omics world. Single 'omics by themselves, the single side node biomarkers, you know, “Harry, you just manage your cholesterol. Noosheen, you can't keep two things in your head. Why don't you just manage your A1C? And Mike, you should watch your blood pressure.” That just doesn't work. There are many, many markers that you've just, as you just said, that we need to keep in our heads. We can't keep them in our heads, but that's where AI comes in. We need to feed them into something and people must have the right to own their data and share their data with whoever they want. If it's their coach, it's their doctor, it's their wife or spouse or significant other, their dog. They should be able to share the data that they own.As long as they provision it properly to whoever they want to give it to because you know, someone doesn't want their employer to know X, Y, and Z. Somebody else wants their coach to know that is people's rights. And coming from kind of a libertarian point of view, I really think people, you know, people should own their own data and they should be able to mix it with other data  for synthesis, if they want to. Harry Glorikian: Yeah, it's interesting. I mean, I totally believe in that. I always, I also understand that people may not understand the implications of sharing sometimes.  And that's not clear, but I do believe that the next iteration of where we're going to see this technology go is multifactorial software programs that can take a number of different inputs to give a much more holistic view of what's going on with me, so I can manage myself better share that information. My biggest worry is most physicians I know are—it's not totally like, it's not their fault, right….Noosheen Hashemi: They're so busy, so they're spending 15 minutes a year with you. And during that 15 minutes, you know, they're taking a point in time, you know, to see a snapshot of your health. And your health is way more complicated than that. We're talking about reverse engineering, 5 billion, years of evolution. And you know, they're going to get, see if such an infinite small part of that. We need to be way more self-aware.Harry Glorikian: Well, it's funny because I do have, some of my physician friends will be like, you want me to understand that genomic marker that whatever, like, I can't, I can't get my patient to manage their insulin level!Noosheen Hashemi: I have a lot of empathy for that. They just don't have the time.  I completely fully understand. Which is why I think we should carry more of the, we should have more agency over our health and we should carry the burden a little bit more.Harry Glorikian: So what is wild success for January? Noosheen Hashemi: Well, we want to keep on this path of developing our multi-omic platform. We want to essentially  help people understand themselves deeply and figure out how to dial their lifestyles and sort of tweak and tune their health. This is non-trivial obviously because there's not enough research in food science or enough research on prevention. You know, out of the $3.8 trillion that we spend on healthcare, 2.9% goes to prevention and 10% goes to acute care end of life care. Just think about that. More than three times as much goes to end of life acute care than goes to prevention. And I'm talking about healthcare costs, I'm not talking about research costs in terms of what NIH and USAID and all of those people spend. So there's not enough research that's happening. You know, people's health data is not organized today. I'm sure there are companies who are trying to organize the world's data. You know, the company that tries to organize the world's data is trying to organize your health data. So I think that's pretty smart.  I think today it's still very opaque and it lives in silos, but I think in the future is going to be mixed.  I think today people just aren't fully empowered yet, you know, with the knowledge and with the agency and with the tools they need to really manage their health.Wild success for us means that people, that we're part of this revolution of consumerized healthcare. We're part of the food-as-medicine revolution, the precision nutrition revolution. So we see ourselves coming up with tools that can essentially get amazing experiences in the hands of millions of people.If you can think about a company like Livongo going public with 192,000 patients. Or if you think about everyone that's playing in the metabolic health today, if you put 12 or 13 companies together, maybe they have a million users, or maybe a million and a half users. Where is that compared to 122 million people that have pre-diabetes diabetes and another a hundred million people that are optimizers? They're either wearing a wearable, they belong to a gym, they're on a diet. You have the entire population as your market. And we have very little that has really made a major foray into health. So wild success means having a product that becomes mainstream. Harry Glorikian: So I think what you're saying is January is moving beyond just CGMs and metabolic syndrome, right?Noosheen Hashemi: Absolutely. Yeah, we, we imagine ourselves, we have built an expandable platform. Our goal is to keep doing deep phenotyping. So we will add 'omics  you will see us adding 'omics beyond what we have today. You will see us  get to other cardio-metabolic disease, you know, cardiometabolic disease, essentially going beyond metabolic disease to the rest ofmetabolic syndrome. You'll see us be ahardware-agnostic company. We want to essentially let people wear whatever they want.  Whatever works for them and, and still try to bring that data, synthesize it and make sense of it and feed it back to them so they can take action. Harry Glorikian: Excellent. Well, that's, that's a great way to end the program with. We have so much more to see from the company and what it's going to be able to do with the data and, and, and help  you know, people live a healthier life. Or like I said, with me I'm constantly trying to measure what's going on. It's just distilling it to make it easily consumable to do what I need to do rather than have me learn statistics so that I can figure it out. Noosheen Hashemi: We have to get, all of us need to get better than that. I remember when I first put on my Oura ring, you know, there's, you know, most people  first when they wear their Fitbits, you know, first it was like, how much did I sleep? And then they kind of learned about REM and sort of deep sleep and then slowly. And then Oura came and then it was like, oh, and Whoop had already had heart rate variability, but then, you know, Oura came in with their other markers, you know, restfulness. And efficiency, sleep efficiency and timing, et cetera. And so people are slowly wrapping their heads around this. It takes a little whil. And yes, January gives you a lot of levers. You know, there's fasting, there's fiber, there's calorie management. There's you know, the spikers. There is the activity counterfactuals—I ate this, but had I eaten this other thing, this would have been my glycemic response. Or had I walked X number of minutes after that, this would have been my glycemic response. At the beginning it's a lot, but that's where it goes back to the experience. We must make the experience enjoyable and better, and we must, companies like us should strive to make the experience enjoyable, make them fantastic consumer experiences like Apple products. But remember Apple's 45 years old and we're just getting going with this, But [Apple is] a great role model. Harry Glorikian: Wellyou know, my doctor may not like it, but I may have to get one of these. He's listening to this podcast. I know that he will, because he always comments on them. Noosheen Hashemi: We're definitely doing that. And you know what? You can have Mike Snyder, you can chat with Mike  about your numbers after. That would be a lot of fun.Harry Glorikian: Excellent. Oh, I look forward to it. So thank you so much for participating. Noosheen Hashemi: Thank you, Harry. It was pleasure.Harry Glorikian: That's it for this week's show. You can find past episodes of MoneyBall Medicine at my website, glorikian.com, under the tab “Podcast.” And you can follow me on Twitter at hglorikian.  Thanks for listening, and we'll be back soon with our next interview.

Having helped to bring big data to genomics through the lab techniques he invented, such as RNA-Seq, the Stanford molecular biologist Michael Snyder is focused today on how to use data from devices to increase the human healthspan. Some cars have as many as 400 sensors, Snyder notes. "And you can't imagine driving your car around without a dashboard...Yet here we are as people, which are more important than cars, and we're all running around without any sensors on us, except for internal ones." To Snyder, smart watches and other wearable devices should become those sensors, feeding information to our smartphones, which can then be "the health dashboard for humans and just let us know how our health is doing."  (You can sign up to participate in the Snyder lab's study of wearables and COVID-19 at https://innovations.stanford.edu/wearables.)Snyder has been chair of Stanford's Department of Genetics since 2009 and is director of the Stanford Center for Genomics and Personalized Medicine. He has a BA in chemistry and biology from the University of Rochester (1977) and a PhD from Caltech (1982), where he studied with the molecular biologist Norman Davidson. He did a postdoc at Stanford from 1982 to 1986 and then went to teach at Yale in the Department of Molecular, Cellular, and Developmental Biology from 1986 to 2009, when he moved back to Stanford. At Yale, Snyder and his lab helped to develop many of the tools undergirding functional genomics, including RNA-Seq, one of the two pillars of transcriptomics (alongside microarrays). Snyder is also known in the world of personalized medicine for having discovered through genomic analysis of his own blood that he was at high risk for Type 2 diabetes, which he later did develop, but controlled through exercise and diet. That work to create an “integrated personal omics profile” (iPOP) was later described in a 2012 Cell article. Eric Topol of the Scripps Research Institute called it “a landmark for personalized medicine” and an “unprecedented look at one person's biology, showing what can be accomplished in the future.”Snyder is the author of a 2016 book from Oxford University Press called Personalized Medicine: What Everyone Needs to Know. And he has founded or co-founded numerous life sciences companies, including:Personalis (precision oncology through liquid biopsies of tumors)SensOmics (genomics + machine learning to screen for childhood conditions such as autism)Qbio (membership-based access to “BioVault” platform gathering numerous biomarkers to predict health risks and recommend healthy habits)January Therapeutics (albumin-encapsulated nanoparticles to deliver drug molecules to tumors)Filtricine (cancer management through “Tality,” a line of foods that cuts off amino acids needed for tumor growth)Mirvie (formerly Akna – blood tests to predict pregnancy risks such as preeclampsia, preterm birth, gestational diabetes)Protometrix (maker of protein microarrays, acquired by Thermo Fisher)Affomix (maker of technology for high-throughput screening of antibodies against human proteins; acquired by Illumina)Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:• Launch the “Podcasts” app on your device. If you can't find this app, swipe all the way to the left on your home screen until you're on the Search page. Tap the search field at the top and type in “Podcasts.” Apple's Podcasts app should show up in the search results.• Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.• Type MoneyBall Medicine into the search field and press the Search button.• In the search results, click on the MoneyBall Medicine logo.• On the next page, scroll down until you see the Ratings & Reviews section. Below that, you'll see five purple stars.• Tap the stars to rate the show.• Scroll down a little farther. You'll see a purple link saying “Write a Review.”• On the next screen, you'll see the stars again. You can tap them to leave a rating if you haven't already.• In the Title field, type a summary for your review.• In the Review field, type your review.• When you're finished, click Send.• That's it, you're done. Thanks!Full TranscriptHarry Glorikian: I'm Harry Glorikian, and this is MoneyBall Medicine, the interview podcast where we meet researchers, entrepreneurs, and physicians who are using the power of data to improve patient health and make healthcare delivery more efficient. You can think of each episode as a new chapter in the never-ending audio version of my 2017 book, “MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market.” If you like the show, please do us a favor and leave a rating and review at Apple Podcasts.Harry Glorikian: Michael Snyder says his life is all about using big data to understand things.He's a molecular biologist, genomics expert, and life sciences entrepreneur based at Stanford University. It's partly thanks to Snyder's work that genomics is a field defined today by big data. In an earlier phase of his career, when he was at Yale, he and his lab members invented some of the fundamental technologies behind functional genomics, that is, the study of gene transcription and regulation, and also transcriptomics, which focuses on the RNA transcripts genes produce.At Stanford he's focused on using big data to transform the healthcare industry, so that it focuses less on reacting to illness and more on proactively lengthening people's healthy lifespans.Snyder is like me in that he's convinced that smartwatches and other wearable devices are going to be an important source of health data. If everyone had one, we could probably detect health problems a lot earlier and make better lifestyle decisions. In fact, about halfway through the interview you'll hear Snyder explain how his own wearable devices have gotten him out of some personal health scrapes. In the middle of one flight to Norway, Snyder says his heart rate went up and his blood oxygen went down. Before his flight even landed, he'd correctly diagnosed himself with Lyme disease and was able to get an antibiotic that quickly cleared out the infection.Later, during the height of the covid pandemic in the U.S., Snyder's lab proved that about three-quarters of the time, they could predict which FitBit users would develop covid symptoms based solely on heart rate data from their devices.The medical establishment hasn't always been receptive to this kind of science. And the era of data-driven collaboration between patients and their doctors has been a long time coming. But thanks to better technology and the impact of the pandemic, Snyder thinks it's finally arriving now.Harry Glorikian: Dr. Snyder, welcome to the show. Michael Snyder: Thanks for having me. Harry Glorikian: It was funny cause I was reading your background and I was like, wow. I mean, so many different aspects of your background, both, you know, from a scientist and an entrepreneur from, you know, helping start, like, I was going through the list of the companies. It was longer than, than I remember. Like, I know quite a few of them, but not all of them. And so I just thought like from a high level, like, how do you explain to someone what you do and why you do it? Michael Snyder: Okay. Well, we're all about big data. We like to use big data to understand things. And these days we want to use big data to transform health. And really that's what my career has kind of been built around. So over the years, we've invented technologies for collecting big data and then we've implemented them. For a long time, when I started out, it was really to try and understand biological systems. People use to study genes one at a time, for example, and proteins, one at a time, we came up with a way of studying them all at once. And that hadn't been done before. And then try and understand them in a systems context so that you weren't really just looking at, you know, if you have a jigsaw puzzle, look at one or a few pieces of the time, we wanted to see the whole puzzle at once as best we could. And so that's really been the philosophy. As I say, it was first choosing to study basic cell biological problems. And then I moved to Stanford now about 12 years ago. And the goal there really was to bring it to medicine see if we can understand medicine, you know, at a holistic level, not just, you know, if you've got high sugar that, you know, you're diabetic. Sure. But are there other things going on as well? Like other metabolic conditions? And that's really the philosophy. Let's look at the whole system, better understand what's going on, and see if we can come up with solutions. Now, the thing, I think that's been a big shtick of ours and at least in the recent years has been focused on keeping people healthy, extending the healthspan as opposed to just doing sick care, which is where medicine is today. So we really want to transform medicine. Harry Glorikian: Yeah. It seems that, you know, health span has become the, the big shift.  And if you look at where we're going from the Affordable Care Act and everything, it's better to, it's more profitable actually to keep someone healthy than just treat them when they're sick. So I like that shift because it brings technology more into the forefront. Michael Snyder: Totally. Yeah, no. And it's going to require a lot of changes and a lot of levels, the whole payment level in the United States is broken. People often only get paid when sick people go in to see them like hospitals, you only get paid to show up when you're ill. We don't put enough emphasis on keeping people healthy because people have said, well, you know, show me it saves money, show me it does it. But until you run those studies, it's hard to do that. So I think the incentive systems are changing. That's slow, but it's also getting  you know, physicians and others used to this concept of bringing in big data to better understand people's health. And maybe to elaborate a little more on this. You know, if you walk into a doctor's office today, it looks pretty similar to the doctor's office of 40 years ago, you know, a few gadgets are updated, but otherwise the same. And guess what the number one user fax machines is in the U.S.? It's the healthcare system. My daughters don't even know what a fax machine is.Harry Glorikian: Yes, yes. It's true. Somebody did ask me the other day, like, can you fax it to me? I'm like, yeah. I think my scanner might, but I don't think I've got a jack that I can actually plug it into to actually send it. ‘Cause I don't do that anymore. Michael Snyder: Nobody does that except for the medical system pretty much. Yeah.Harry Glorikian: So, you know, you've had you, you mentioned it, you had a hand in, in, you know, developing these foundational ideas and technologies in functional genomics, such as, you know, high throughput protein sequencing techniques, you know, known as RNA-seq and then making transcriptomics possible. Like, can you talk about what it's been like to sort of, you know, develop those technologies and then, you know, be at the forefront of trying to answer these big molecular biology questions and, and what in your mind, what came first? Was it, I gotta answer this molecular biology question so I'm actually, I'm going to develop this instrument and then be able to answer that question. Does that make sense?Michael Snyder: Yeah, it's a little of both to be honest. Often we develop technologies out of need or out of observations. We have, so for example, in RNA-seq, we were trying to map where all the transcribed regions were, where all the genes were in yeast, which was the organism we were studying at the time. And we tried this one now very outdated method that just work miserably and we just stepped back a minute, said there's gotta be a better way. And so that's how we came up with, we thought about it, came up with a way and then implemented it and, and showed it worked. And then of course if it works, it takes off quickly, very much like CRISPR. And that's been true for other things. In some cases as we'll make an observation like when we first  invented a way to map the targets of key regulatory proteins called transcription factors there, we saw that these things were, were giving these dots in what's called the nucleus of the cell. And we said, well, where are those dots located? And so we came up with a method for figuring out where are all the, where all the binding sites for our, for these key regulatory proteins. So it's, it's been a variety of ways. And then when it's come to medicine, we, once we invent the technology, so well, people will say, well, well, how can we use these now in other ways that would be beneficial. And I'm not sure what you know, but I was at Yale for a long time, and I had a great time, it was fantastic place, but I was more on the main campus and it was just harder to implement them into medicine. And then about 12 years ago, I moved to Stanford and I'm right in the heart of the medical school where there's all these clinicians and very eager, beavers around, trying to figure out how to better, you know, do medicine these days. And so it's just been easier as we've implemented technologies to roll them out and see how they might work in the clinic. And so I think one of the biggest projects we launched when it came to Stanford was we call it personal 'omics profiling. The idea, you collect a lot of deep data around a person and you do it longitudinally. So we'll, we'll sequence their genome we'll look at all the molecules we can in their blood and urine, meaning their RNA and their proteins and their metabolites. We, we do deep questionnaires and clinical tests on people. And then, and then, yeah, about eight years ago, we sort of got into wearables back when they were just fitness trackers, realizing they would be powerful. So the idea was to collect data on people—while they're healthy, by the way, not while they were sick, while they were healthy—and do it longitudinally, do it every three months and see how they change. And if they got ill, then we collected more sample. And that was the idea. That's turned out to be a really flagship project, I think, for just how we might better implement health. And you raise the issue about starting companies. So a little of my philosophy is I think academics are great at discovery. They're great at proof of principle, but they're not good at scaling. They think they are, but they're not. And this is what companies are just fantastic about. So we've spun off, we think some, what I hope will be powerful companies. One was a DNA sequencing company called Personalis. They've done very, very well.Then we've spun off Qbio, which is doing sort of a, you know, a more commercial version of this personal 'omics profiling, as I mentioned, but they added on whole-body MRI and have some other things that are pretty powerful. So they've, they've got a medical version of, a more actionable version, again, our academic lab is doing this research for us and trying to figure this out, but the company can do it, implement it.And then we have another company, January AI, it's doing continuous glucose monitoring for trying to better control diabetes. So again, we figured out some things in the lab and then it made sense to commercialize it. So, so it all goes kind of hand in hand to me. It all makes sense. And it's very satisfying by the way to do stuff in the lab that, that we think is impactful and then try and get it out there to a broader group. We think that's how you scale. I don't think academics are capable of scaling. Certainly not very well, whereas companies are. Harry Glorikian: Well, yeah, I mean, I, you know, quite some time ago being a product manager, I mean, you, you, you had to like your biggest accomplishment was getting that thing from the bench right out into somebody in the field and, oh my God, it actually, yeah, it did something. Right. And that was the exciting part. Stopping at the research, I would have been like, “That's it? Like, all I got was all I got was a paper out of it?” Like, no, no. I want to, you know, I know that that's always the beginning. Michael Snyder: Yeah, we got excited about the papers, absolutely. But we're very also, it's just fun to see it get out further. Totally. And again, so that's literally all the companies, maybe with one exception have spun off of the things we were doing in the lab said, all right, we get it. Now it's time to scale this out and develop it into something people would be interested in. And it is very satisfying, as you say.Harry Glorikian: So, so, you know, I mean the genome has come down in cost. I mean, a lot of other analytic technologies have come down in cost. I mean, I know the latest thing that Illumina has said is they want to get the genome down to like $60 to do the functional work. Not necessarily the analytics or analyzing part of it. How do you see that changing what you're doing and the impact? I mean, you've got a lot of data, so I feel like you can almost. paint a picture of the evolution of a person.  If you could sort of see the initial traces, how do you see this playing a role in what you're doing and the impact that it's going to have on where it's going next?Michael Snyder: Yeah. I think getting the cost down is a big deal because when we set this up as research, it was very, very expensive. And so  getting it out there will help, especially when you're talking about keeping people healthy because people don't want to dump a lot of money into a healthy person. 'Cause they don't know that—here's a problem with our healthcare system. Most people will shift every 18 months, that's the average time people stay with their provider and then they'll shift to a new one. And that may be because their company's shifted. Not necessarily they did, but their company may have done it. And sometimes they change their job, they shift. So  that's whyIt's a barrier then for, for providers, healthcare providers put a lot of money into you, when 18 months later you're going to be with somebody else. But if the costs are pretty cheap, like the genome sequences, let's say, but the interpretation is $200. It's worth it to you because then it's a lot easier to execute preventative medicine, get your genome sequenced, predict what you're at risk for, and with a fairly low cost. But if they're going to dump $2,000 and you're going to be with somebody else, there's a lot more balking, if you know what I mean.So I think, I think keeping the costs down is a big deal. Qbio, for their exam, they charge $3,500, and on one hand that's a lot of money and we, we like people to do it two months. You get a whole-body MRI and other things. On the other hand, we would argue for it. It should save and already has. We found like early prostate cancer, early ovarian cancer, early   pancreatic cancer, which is a big deal and some heart things and stuff like this is from the first a hundred people that we did. And it's more now. So, so we show it has utility. And of course, if you're one of those people, it's a big, big deal. So, and, but by getting the cost down, it just gets the whole barrier away. Right now you have to pay out of pocket because there is no reimbursement. So the cost gets down and I think people would reimburse because there'll be willing to run trials to show it does work and saves money. So I, I think the whole thing will go together as costs drop, and we can expand this out and show utility. Harry Glorikian: Well, and you know, if you think about the implementation of technology, like if you could carry it around on your iPhone, when you go to your next physician, and you've got it with you right at that also brings the cost down rather than have to do everything all over again.Michael Snyder: Totally. Yeah. In the future. And I think physicians are just warming up those. There's an education side of this from the physicians, you know. When we first got involved in the wearable space, they would tell us how inaccurate it was. And they didn't like the idea that your iPhone would be so powerful. Possibly more powerful than they are. There was a threatening aspect of the whole thing. And I think they're now reassured that, first of all, they're very important. They're not going away. There's these technologies to augment what they're already doing. And, and it's, there's an education side. I remember when genome sequencing first came out, even at an enlightened place like Stanford, I would talk to some of my colleagues and they'd say, well, nobody shows that really worked, you know, and it's got a lot of errors. They just think about the negative. The instant reaction is, you know  we don't really know how to do it. You might tell people something they're not going to get. That's harmful and, and try to tell them, well, look, you have just educate people and educate the physicians. And now, when we first started actually, you know, cancer, even people were pushing back  and cancer is a no brainer. You need genetic tests or sequencing. But for elderly people, it was a strong pushback, right? Everybody's telling you, Mike, what you're doing is really harmful to people. You're going to get people to turn them into hypochondriacs when you sequence their DNA. And now there's some, some people feel that way, but most people have kind of warmed up or at least maybe it's 50-50 are receptive to the idea. Maybe it is a good idea to get a, to find these risks. From our standpoint, just from the first 70 people we sequenced the genome, we found someone's BRCA mutation. And now that person out of mutation suggests they might have certain kinds of cancer. They did a whole-body MRI that early thyroid cancer, we caught that had it removed, saved their thyroid, the rest of their thyroid. That is, you know, very, very useful. Another person, a very young person had a mutation in a heart gene and would have been at risk for cardiomyopathy. It turns out his father died young of a heart attack. And so he had this mutation, we saw this thing and sure enough, he had a heart defect. Didn't even know it. He's on drugs now. So, so these technologies can be very, very useful, very, very powerful. But you have to show physicians that, and then they sort of go, “Oh yeah. Now I get it. We kind of get it.” They may say, well, show us the evidence. And so that's what we're trying to do. Harry Glorikian: Yeah. I mean, I just. I've got a book coming out in the fall and I just interviewed somebody who had done participated in BabySeq. Robert Greene's thing, right? And identified an issue  that had a profound effect actually on the decisions of the mother, not the baby.  And so it's an interesting story when she went through it, I was like, wow, that is super impactful. You know, it adds a lot of, you know, it is funny. She said, you know, we did this and I was not expecting this. Right. So it was an eye opener, but it's affected her decision-making going forward.  And it's along the lines of BRCA, what she was informed of, but  I'm sort of saving it for the book. So when it comes out in the fall. Harry Glorikian: But you know, you wrote a book back in 2016, that introduces non-experts to personalized medicine. You know, you covered everything from how DNA works to the applications in genomics, in cancer. So. I almost think like that might need a refresh or at least the publisher might want to put it out again, because I think people are more interested now. But if you were writing that book from scratch today, you know, five years later  would you write it at all? Would you, the field is, I feel like it's exploded in the last five years on the one hand. On the other hand, I still feel like I talk to people that still don't understand the impact of it. So I feel like I'm talking to both sides sometimes, but. How do you think the field has changed in the last five years? And where do you see it going next? Michael Snyder: Yeah. Great question. So when we wrote the book, you know, people really didn't like this area. They didn't like it, sequencing genomes and things. They thought it was harmful.  And the same idea where, I mean, we literally collect millions of data points. Every time we sample someone, then people still bring it up. And so it was really, the goal there was to educate people about what the technologies are, what they're capable of, and this sort of thing. So I think we have come a long ways since then, where the field was mostly against. I asked people to raise their hand. How many of you want to get their genome sequenced? Usually there's a small fraction, even in an educated group. Now it's probably the majority. If they haven't even done it already—they may have already done it. So  I think the world has changed. I think what I would do is update the power of the new technologies. New technologies have come out, even since we first put that book out.So I'd add more. Expand the wearable space. I just think we can put a smartwatch on every person on the planet. If we wanted to a very inexpensive one that would be a health monitor for people. And, and there would be a no better time for that than this pandemic that's going on now, because we actually can show, we can tell when people are getting ill prior tosymptoms from a smartwatch, from covid and other infections. So we can talk about that more if you like, but it's a pretty cool study. We can show again, 70% of the time, we can tell when you're getting ill, because your heart rate jumped up, and we pick it up with a smartwatch. So imagine putting that on everyone in the planet and just letting them know, “Look, we can tell when you're getting ill.” You know, even if it's not perfect, a bunch of the time that we think would be very useful. They don't send their kids who are sick to school, affecting everyone, or it shows up in a nursing home and, you know, you flag it right away. And that would be, we think very, very powerful.I view it as analogous to, you know, a car. A car usually has several sensors. Some have as many as 400 sensors on them. And you can't imagine driving your car around without a dashboard, the gas gauge or, you know, a speedometer or an engine light or all these things on we've gotten so used to this is what you do when you drive a car.Yet here we are as people, which are more important than cars, and we're all running around without any sensors on us, except for internal ones. They're okay. But they're kind of slow. And I just, to me, it's just totally logical. We should all have our own, you know, sensors on us. It's the car health dashboard. Our smartphone will be the health dashboard for humans and just let us know how our health is doing. And it doesn't mean when you see a light go off that for sure something is wrong, but it gives you a heads up. And it has, you know, in, in some cases our profiling has really had life-saving consequences.Harry Glorikian: Yeah. And I'm, well, I mean, it's funny cause I think about these things and I look at a lot of these technologies and. You know, it's always a single biomarker of some sort, right? That that's, you know, a heartbeat or temperature or something. And then I think about, well, the next level has got to be a combination of them, which makes the predictive power that much better. Michael Snyder: That's right. Yeah. We call that multivariate, yeah, where you bring in several features. So you start seeing it enlarge something or a thing on an image, and then you see that those biomarkers of those. That's how we discovered someone with an early lymphoma in our study that had an enlarged spleen, and then we saw certain markers are up in their blood and said, something's not right here. And then they did follow up and sure enough had early lymphoma, no symptoms yet. So again, caught it early, a lot easier to manage just much better off. We have a number of examples like that. So the combination tells you. And the other thing that's very under appreciated is the longitudinal profiling.  People don't realize that if you go in and get tested now, and they rarely look at your old measurements. And so they just see if you're in the normal range and you can be at the high end of the normal range, but you're still “No, all right, you're fine. Don't worry about it.” But if you look at your trajectory, you know, maybe you've been running kind of normally in the low normal range and suddenly this one jumped up, you know 50%. You can still be in the normal range, up 50% and something's headed in the wrong direction and you would be ignored for that. Whereas if we just had very simple algorithms that can flag that sort of stuff. “Look, you're not only up in this marker, but you're up in that one too, which is related, you know, maybe something's going on early.” Let's see what's going on there a little better and catch things earlier again when you can manage it better. So, so I think we ought to bring in longitudinal information again, to me, that's why the wearables are so powerful because they measure it 24/7. Harry Glorikian: Well, I do that with my, my physician. I walk in, I'm like, okay, here's my data for the last, you know, X amount of time. And it's funny because even I've noticed, like during covid, cause I was much more sedentary, like certain things were going in the wrong direction. And I was like, oh no, no, no, no. I got to get those, those back in line. If I didn't have the ability to look at it over time. And I was only looking at that one point, you know, how am I going to see where it's going? Michael Snyder: Out of context. Yeah. Here's another thing that's wrong with medicine today. It's all population-based, so they will make every decision about your health based on population averages and hence that normal range. But again, you may not at all be like normal population levels. And so you've been told, and here's my favorite example, you've been told since day zero that your oral temperature, when you put it thermometer in your mouth is 98.6, but it turns out, first of all, that number is wrong. Yeah. Average temperature is 97.5. But more importantly, there's a spread. So the what's called the 25th quartile is 94.6. So four degrees below and the 75th quartile, 99.1.So in today's world, if your normal baseline temperature is 94.6, that's your healthy temperature, and you walk into a physician's office at 98.6, they'll tell you, “You're healthy. Everything's great. What are you doing? Go home.” But you're at four degrees Fahrenheit over your baseline. I guarantee you're ill.  This is just, it's not healthy. So you got to know your baseline. And for me, by the way, mine is 97.3 and it's been dropping a little bit over the last 10 years. Which is, there's some studies suggesting that is the case actually, so that people do drop a little bit as they get older. But the point is that, you know, my baseline is not 98.6, if I am at 98.6, I am ill. [music interlude]Harry Glorikian:I want to pause the conversation with Michael Snyder for a minute to make a quick request. If you're a fan of MoneyBall Medicine, you know that we've made more than 60 episodes of the show. And you can listen to all of them for free at Apple Podcasts, or at my website glorikian.com, or wherever you get your podcasts.There's one small thing you could do in return, and that's to leave a rating and a review of the show on Apple Podcasts. It's one of the best ways to make sure that other listeners will find and follow the show.If you've never posted a review or a rating, it's easy. All you have to do is open the Apple Podcasts app on your smartphone, search for MoneyBall Medicine, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but it'll be a huge boost for the show.Thank you! And now back to the interview.[music interlude]Harry Glorikian: You know, just talking about the wearables, because I noticed like earlier you had at least four devices and I think an Oura ring, or maybe… Michael Snyder: I lost it recently, but yes, I normally wear, I normally wear eight of these devices. An Oura ring and four smart watches. I have a continuous glucose monitor and environmental sensors. I've got all kinds of gadgets. Harry Glorikian: Oh Jesus. Okay. Well, so tell us where you see the overlap of these digital devices and the personalized medicine sort of coming together, because I feel like one is much earlier warning system or could be an earlier warning system of what may come in the future. And one is a current monitoring system, of how the machine is working. Michael Snyder: Yeah. I mean, I do think they're an integral part of personalized medicine.   Only now I think people are realizing the power. The pandemic, I hate to say it, helped with that because remote monitoring is now become popular and the concept that you can start managing people.So, a little background, we started on this about eight years ago, when the Fitbit was out there. And people are using these fitness trackers. We thought, well, gosh, these are pretty powerful health monitors because they're measuring your heart rate and they measured 24/7. In fact  you know, the first device we used doesn't exist anymore, a Base watch, it takes 250,000 measurements a day. Now some of them will take 2.5 million measurements. They really follow you in a deep way and they'll measure heart rate, variability, skin temperature. Those can all be pretty accurate, by the way. It depends on the device. Some will measure blood oxygen and even blood pressure. Those are less accurate, but their deltas are pretty good, meaning the changes. And then there's other things out there too, something called galvanic stress response. So they can measure all kinds of things. They're always following you. So we think that's super powerful. Now when we first started, again, physicians pushed back and said, well, you know, everybody knows they're not accurate and we actually want paper coming out. Very soon [they started] saying, well, actually they're more accurate for some measurements, like heart rate than what you measure in a physician's office. My heartbeat can vary by as much as 40 beats per minute, depending whether I drove their biked there. Even if I rest at 15 minutes, it's still different and whatever's going on in my life.And, but if I pull my resting heart rate off in the morning, first thing it's pretty constant, unless I'm either stressed or ill. So you actually have better measurements from some, for certain kinds of measurements from these devices. So that's the first thing you have to show, show them they are accurate and things. So we think we've done that in some cases for some kinds of things. So I think we now just need to get physicians to start thinking about that more and get them as an integral part of your healthcare. That when they show up, they don't have to take your heart rate anymore. They'll just read it from, it'll already be pumped into the system. You can already have it there, and they can follow your trajectory. Since the last time they saw it last, whatever month, six months, two years, what have you, and see what's going on much, much better than these static measurements that they take every few years when you're healthy.So I just think they're going to be super powerful for following your healthy physiology. And then when you get ill, it's all about the delta, the shift from your personal baseline. And what's powerful is because we all have different baselines, different heart rate, different blood oxygen, just what have you. When you shift up, you can figure it out. And the way we got in the most was from our first work, we actually showed a, I actually figured out my Lyme disease. I picked it up from my smartwatch. I suddenly got a pulse-ox, a blood oxygen. And it was because my, my heart rate went up. I was flying to Norway, of all things, and my heart rate went up much harder than normal. And my blood oxygen dropped much lower than normal. And I saw it on the airplane and it didn't return to normal after I landed. And I knew something wasn't right. I thought it was Lyme disease, because two weeks earlier, I was in a Lyme-infested area helping my brother put a fence in in Massachusetts. Most places are Lyme-infested in Massachusetts.And then I saw this and I, I warned a doctor there. It might be, that's a classic case, I warned him, it might be Lyme because of the timing. And later got, by the way, I didn't have symptoms. That was a key. I saw these things before symptoms. I later had symptoms, went to a doctor in Norway. He pulled blood said, yep. My immune cells are up. I've got a bacterial infection. And he wanted me to take penicillin. I said, no, I should take doxycycline. The classic case of, you know, you have to take charge of your own health. He pushed back, but he did give in, in the end  And, and it turns out it cleared it up. I took it for two weeks and when I got back, I got measured. Sure enough, I was Lyme positive, by a sero test and I give him blood right before I left I was negative, so I seroconverted, a very well controlled experiment. The point of all of this aside is, I can figure out my Lyme disease from a simple smartwatch and a pulse-ox. And so that showed the power of these smartwatches for doing this sort of thing. And then that's how we got, we looked into the data and saw every time I got ill from respiratory viral infection, including asymptomatic time, I could see the jump up in heart rate. So we knew it would work for infectious disease. And then when the covid pandemic came, as you might imagine, we just ramped up or really scaled out that study.We are device agnostic. So we rolled out the study in a two part manner. So meaning we first wanted to show that our algorithms and perfect algorithms for detecting covid-19. So we partnered with Fitbit  but also talk to other groups as well, pulled in data. We started with Fitbit, we could, right away, we got 32 people who had been covid-infected  with their Fitbit watch still running. Some people let them burn out.  But we, we, and we had a diagnosis date and a symptom date. And so we could actually show, we initially showed that for 26 of 32, we could see a jump up in resting heart rate from a simple smartwatch, in this case a Fitbit. And we had several different algorithms, both steps and a resting heart rate. We, we showed the algorithms work and then we built what we call it a real time alerting algorithm, actually two of them, we tested them out and they seem to work. So then in December—and we love all of you listening to this to enroll in our study at innovations.stanford.edu/wearables—anyway, what we did in December is showed, we rolled out a real time alerting system that will actually send off a red alert when your heart rate jumps up. It works about  73% of the time. We have 60 people have gotten ill, a little over 60, and we can see those red alert will go out before at the time of symptoms in 73% of cases. And we even now caught two asymptomatic cases where their heart rate went up. They had no symptoms but they happened to get tested and they were positive. So we can show that this thing really does work.  And so now we're trying as the say we are building an infrastructure to roll this out for millions and millions of people.Harry Glorikian: That's good because I was just thinking it would be great if these things would proactively ping you and tell you there's a problem rather than you have to look at them all the time and see where you are compared to baseline.Michael Snyder: Yeah. The one minus is you have to open your app and sync it, and we're trying to do exactly what you just said, set it up so you don't even have to open the app. You probably have to leave it open, but we want to be able to ping you. We have to get IRB approval. That's our review board approval, but we want to do exactly what you just said. So right now you just have to check it out every day. You open your app and you'll see, oh, do I have an alert or not, when you wake up. Do it first thing in the morning. And if you have an alert. We're not allowed to give a medical recommendation but we could say, look, you have a jump up a resting heart rate and I'll let you figure out how to interpret it. But ultimately the plan would be to say, you know, Gosh, maybe you don't want to go to that party tonight or go to work and maybe you want to go get tested for that. Something could be up. That's ultimately where we want to get to with this alerting system. So, and I don't think it will be too far away where we're showing it, where it's going to pull in more kinds of data. So we can get that 73% up to 95%. That's our goal. Harry Glorikian: Yeah, it's interesting. Cause I was talking to just the other night to a friend of mine who's a primary care physician and she was saying, “Well, you know, these things are not very accurate and you know, people are going to come in for problems.” I'm like, okay, hold on. They're, they're actually pretty accurate. They take a lot of data over a long period of time. So, you know, those blips, I can sort of, you know, wipe them out if it's a truly a blip and I can see a lot of information. And it's more accurate than me coming in that one time you'll see me. But the other thing I said to her was, you know, you realize like this is just going to get better. Like the more and more data we have, the better and better these things get. And at some point it is going to be like the standard of how things are done. And it's, I think it's difficult for people to understand that more data, better algorithms. You know, better equipment, all of them coming together. You just end up at a place where you're going to, this is going to be the standard.Michael Snyder: A hundred percent agree. A good case is, imagine if we told people you can't own a thermometer. They're medical devices, nobody should have a thermometer. That means that, you know, nobody would be taking their kid's temperature. By the way, a thermometer is a terrible way to tell if you're getting ill. It's an okay way, I should say. Your resting heart rate is way better. When you show that, that it's kind of funny. A thermometer is a 300-year-old technology, very ingrained in our medical system, and it has some value. Don't get me wrong. But it's not as good as any of these other technologies. We can pull off a smartwatch like resting heart rate and other signals and soon respiration rate, all that stuff you can pull off and you'll have a much better signal for when you're getting ill than a simple, stick a thermometer in your mouth.And it's going to go way beyond infectious disease. One thing we can show, we can get a signal for something called a hematocrit and hemoglobin from a smartwatch, and we can, and that actually can be an early sign that following those levels can give you a clue as to whether you're getting anemia.We have another signal coming from a smartwatch about diabetes, something called insulin resistance with diabetes. So we can get, they're not clinically diagnostic tests. So that, and they're just, they're kind of hints if you know what I mean, but very valuable hints. We think, oh, you see this and you see this change, maybe you should go to a physician and follow up on this. And there's some measurements from a wearable that there isn't even a clinical correlate for. There's something called galvanic stress response, which is conductance on your skin that you know, there is no medical, typical medical correlate for that yet that's a valuable measure. If you're stressed, you will sweat more. If your diabetic you'll have drier skin, it'll give you a signal towards diabetes.So these measurements we think are going to be very, very powerful. No one measurement, it comes back to what you were saying earlier. Multiple measurements together will help give you a better idea of what's going on and clues that something may be up that alert you while you're still in this, you know, fairly healthy state, we hope and can then take the right course, the right intervention course Harry Glorikian: You almost wish there was a spider graph that had your normal, and then show deviation from normal on these multivariates. So you could evaluate it over time. I mean, I find myself having to go, I have to go to that one and I have to go to that one. Then I have to go to that one and it would be a whole lot easier if it was in one format or one graph that could show me where things are. Let  me ask you a question…   Michael Snyder: By the way I think those integrated systems will happen. Yeah. And your car dashboard is a good example, right? There's aren't usually single or single sensors that are triggering. Sometimes they're integrating multiple sensors to set up a signal and that'll be true for your health. And just the way the data is organized again, in our antiquated healthcare system, it comes back because to these individual measurements, whereas instead, you want this as well here, here's your cardiovascular panel, you know, with the five measurements all together and these other panels around systems to tie and even some broader panels besides that, so that you can see things in this more holistic fashion. And another analogy might be, you know, when a pathologist reads images, they write up a report which they give to your physician. Hour physician can't read a pathology image slide to see if you have cancer not, but they can read the report that pathologists get. And so I think that's how we need to integrate these data. To put it in a usable fashion. To be honest, it's not just for the physician, but for the consumer, because they're the ones who can act on it most quickly. They're the ones who are going to have the most time to think about the information. Again, another flaw, and it's, it's no negativity to the physician, but they only have 15 minutes to spend with you. At least in the U S you know, you get a half hour appointment, the physician's only there 15 minutes, they glance at your chart. They do a few things. They make a quick assessment and they're off to the next patient. Then they have to write it up manually. Ironically.  And then  you know, you have a lot more time to spend thinking about what's going on. So if you have this information accessible to you, something doesn't look right. I think it's a better chance for you to take control. It's like me and my Lyme disease, you know, if I wasn't watching what was going on, I don't know what would have happened. It was very valuable for me to have that information. Harry Glorikian: No, no. I mean, I, you know, it's funny because I was, you know, we're using these machines all the time and  you know I try to be as deep in the space as I can be. But if there was an algorithm or a series of algorithms, looking at different data streams that are coming off of me and can sort of be like  my friend, right? Whether it's weight or heartbeat or blood ox or something else that could sort of highlight it for me and then put it into a format that is easy for me to digest. Either graphically or, or a few words. I mean, it would be a lot easier for me to manage myself. Michael Snyder: Yeah, it's coming. I think it will hit, but you're right. I mean, again, medicine's conservative. If you do belong to, you know, Fitbit, or there are certain programs. Or Apple. They'll ping you, you know, here was your weight this week, you get these, but we're just at the trivial stage of what can come. Obviously I think what you're saying, where you would integrate different data types and then see these, and again, in this paper we'll have coming  out soon weshow that you can actually follow people's trajectories and set up AI systems, artificial intelligence systems, follow people's trajectories to look for these deviations. It's still very, very at the early phases. I think they're going to be super powerful for managing chronic diseases like diabetes, obesity. There's something called chronic fatigue syndrome that a lot of folks have, and they have crash days and good days. And to be able to tell all these things are associated with your crash days, watch out for those trying to avoid those. These are your good days, do more of those. It's very, very true in the glucose monitoring space, diabetes. People don't realize it's the next endemic, if you don't realize that. 9% of the us population is diabetic 33% are pre-diabetic. And 70% of those are going to become diabetic. By 2050, they estimate half the population can be diabetic if we keep going the way we're going. So  we need new intervention plans while people are healthy. Don't wait until they're already diabetic and have problems.And this is where the continuous glucose monitoring technology I think is going to be really powerful. Figure out what spikes you. It's very personalized. What spikes you is very different from what spikes me. Right. And be able to see that. I don't know if you've ever worn one, but they're just very, very powerful. And so it's, again, one reason why we formed a company called January AI to help help with that. Harry Glorikian: Well, it's funny because my wife was asking me, she goes, you know, I'm wanting, I'm thinking I want to wear one of these so that I can see what I eat, sort of how it affects me, but it's all by physician prescription. Go and convince your physician, you know, Hey, by the way, I need a script for this. Michael Snyder: Yeah. So  two comments there. One is in Europe there is no prescription, you can get over the counter. So there's less regulation. So they're ahead of us on that. I think it'll happen in the U.S. Right now you do need a physician, but there are studies, there are groups rolling out. So again, I mention ours, but there are others as well. But with January AI, their case. They'd take it even further and you get this continuous glucose monitor for, for 28 days and do the program longer. But you can, it not only shows you what spikes you, but they also train you a little bit, meaning you eat, you know, your favorite food or it could be rice, what have you. Rice, by the way spikes almost everybody. And then the next day you did the same thing. You do it for breakfast, you do the same thing and take a 15 minute walk and it shows how it suppresses your spike. So it's a, it's a behavior intervention program as well. So it teaches you. And we think that's kind of powerful as well. You not only want to get the data in and have people learn from it. And this thing does food recommendations as well.  You want to be able to teach people how to live better, healthier lives as well, doing an intervention, as they say, Harry Glorikian: Oh yeah, yeah. I mean, I think that, you know, some seeing it so that the data convinces me and then understanding what I need to do to fix it is also very useful. Right. So. Do you think we're ever going to get to? You know, I know that we have data-driven healthcare. Everybody always likes to say we are data-driven, but I mean, truly, like I don't make decisions on businesses without really understanding their profit and loss where their costs are, what their spent. I mean, very detailed analysis. Do you think that we're going to get to this point of [going] beyond hunch-driven medical decision-making? What was that show, oh my God, where the doctor would sort of put all these pieces together and then come out, with a famous actor, I forgot the name of it, but—House yes, yes. House. That was it. I mean, do you think are going to get to more data-driven. I feel like we should be there already in some way. Michael Snyder: Yeah. So, you know, I'm very Pollyannaish. I believe the answer is going to be yes.  I'm like you, I feel like we should be a lot further along and I just think that's the conservative nature of medicine. People think, you know, do no harm. And so they do nothing. And I would argue that doing nothing is harmful.  So I do think we need to get these, the, you know, this data integrated better. I think the best way is to roll out studies like the ones we're doing and others that can show it has power has impact. And that's how you convince people.I'd love to come up with a way to accelerate it. I think programs like this are a really great way to do it. A lot of this stuff is going to be consumer driven. I mean, people are now wearing smartwatches not just for fitness tracking, but for health devices, which is itself now the new concept.So it's coming. And luckily they're fairly inexpensive. I think that's the way it'll happen at, you know, when a lot of new technologies roll out, they are pretty expensive and then only the wealthy can have access to it. But the hope is that as the wealthy uses these and shows it has utility, then the price drops and they get out to everyone. Certainly that's how genome sequencing started. And I think it will be true for a lot of these other technologies. Luckily, smartwatches are pretty cheap to begin with. So even a hundred-dollar smartwatch is a pretty powerful health device, I would argue. Harry Glorikian: Yeah. I mean, you know, if, if Illumina achieves its $60, right, for the function—I've been looking at an analytics approach that will bring down whole genome sequencing to $60. So if it's $60 to do the actual work, the wet chemistry, and then $60 to do the analysis, I don't think there's many barriers in the way anymore. Michael Snyder: Yeah,totally, and we're not so far away where people will they'll get their genome sequenced, but now there are technologies to look for early cancer by sequencing DNA in blood, and you knowHarry Glorikian: Liquid biopsy.Michael Snyder: So GRAIL and Gaurdant are leaders there. My company, Personalis is, I think, doing all right. So anyway, that's a, those are areas that we think are going to be powerful and soon they'll become routine tasks, once you show utility. But no company pays for it right now until you show that gee, you do this on healthy people and it doesn't cost the company $5 billion to find three cases, which I won't  yeah, that then it'll roll out.So right now, and the way this works too, for the liquid biopsies, it's looking for, they use it for cancer recurrence, if you've had cancer, you try and see if it'll appear again. And that's very logical. They'll demonstrate utility there. They already are. And then soon it'll be early detection and that'll go to the high-risk families. And it always comes down to who pays and insurers won't pay unless you're at high risk generally. And then soon if it's cheap enough, comes back to your point, if it's cheap enough. It'll be there for everybody. Harry Glorikian: Yeah. I have this vision that you're going to go into your CVS or your Walgreens and you, you know, once a year or whatever, and we're going to see things so early that, I'm hoping one day in my lifetime that people will be like “Cancer. What, what, what, what happened?” Like you were able to get so far ahead of it, that it stops becoming an issue. Michael Snyder: “What do you mean you detected cancer only when you saw this giant lump what's that all about?” Harry Glorikian: Yes, exactly. Exactly. Michael Snyder: Yeah. I'm a hundred percent with you. Yeah. Harry Glorikian: So let's say we start, I mean, implementing this at a much larger scale, and broader than what we have now, because I think you and I are probably way ahead of a lot of others on these things. But do you see that effecting a longer life, or do you see it—like, I'm trying to weigh healthspan and lifespan, right?Michael Snyder: Well, it's all about healthspan, yeah. It's all about healthspan. You want to extend the healthy life.  You don't want people hanging on in miserable fashion for years. I think anyway, that's, that's my own view and I think it'll definitely extend healthspan because you'll catch things while people are healthy, not once they're ill, and then you take corrective action and keep them healthy. I think it'll totally extend the healthspan. And the goal is to do that. You know, you want have people that have held a healthy life and then just die. That's how it should go. Harry Glorikian: That's yes. My, my grandmother used to say that when I was younger and I thought it was morbid. And then now as I've gotten older, I'm like, Nope, Nope. That's, that's a good way to go. Like if you're just going to go go, Michael Snyder: Yeah, I think so too. We all know cases where people say, well, at least they died quickly. And we all know cases where somebody is hung on for three years and a lot of pain and very miserable fashion. And I don't, again, at least my own personal view is that that's just certainly not what I want. And those probably should be personal decisions, but minimally, regardless, everything we've been talking about should extend the healthspan, catch things while people are healthy, see these trajectories heading in a bad direction and then take corrective action. And that will have the desired impact. Harry Glorikian: So, one, one final question, before we go. Who do you think  is going to drive that? Is it going to be the healthcare life sciences world, or is it going to be the technology world? That's quickly encroaching. Cause it's, it's not Pfizer that's making this device on my wrist, right? It's, you know, all the other companies you can name. Michael Snyder: Yeah, no, I think it's kind of, ideally it would involve everybody partnering together, but you're right. Technology is having a big impact because consumers are eager for this information, as they often are. And especially as the word gets out and people like you and me start, you know, espousing the wonders and the power of those, these technologies.So I think there's that part. I do think we've got to get all the shareholders aligned, meaning I think employers as well should be big incentivizers of this. Meaning it pays for them to have their employees healthy. And that could be a plan I offer. If you're a big employer, maybe you have your folks enroll in one of these, you know, preventative plans, a hundred bucks a month, keep them healthy. You save a lot of money. I do think it helps to incentivize the users as well. I think people are often lazy. But they're, they're all concerned about their pocketbook and their loved ones.So I think the two ways to incentivize people are give them, you know, discounts on their insurance if they walk their 10,000 steps and you got to come up with ways for them not to cheat  or, or do various things. But  I, I do think that will help. Or you relay their family members who like egg them on a bit. It's because sometimes that's very incentivizing. So I think we need, we need to have good incentive ways to do that.I think financial incentives are one of the better ones. And again, that can relay back to the employer. The employer can offer these plans and then give people bonuses if they do, they're supposed to, you know, if you, if you are overweight and lose weight you know, maybe that would, well, you don't want to be able to get overweight and then lose weight, but you want to incentivize people to lose weight.Anyway, you come up with the right models for incentivizing folks. So, so we need to get the financial models in place. We need to show the stuff works and the technology is going to keep improving, getting cheaper, et cetera. So it's all going to go together, I think, in parallel. And then people like you and me will be out there saying, man, this is amazing. Everybody should be doing this sort of stuff. Harry Glorikian: I say it now. It's just tough to get everybody on board. Michael Snyder: Yeah. People are still scared. Yeah. But that'll go away. Harry Glorikian: I hope so. I hope that physicians get less scared. That's my biggest hope. Michael Snyder: Yeah. We've got to educate them. And those folks, you have to show that it works, that it has power. But they do have these refresher classes, they call them continuing medical education, and a lot of physicians do that. And I think it's a great way. I give a lot of talks at those, as a way to try to, I think, at least show the potential of what we're trying to do. And I think some of them buy it and some of them don't. Harry Glorikian: Yeah. And, and, you know, I think it needs to be integrated into their technological solutions to make it easier for them to sort of absorb it. And the current systems suck. Michael Snyder: That's true. Very true. Yeah. Yeah. They say, well, how do I have time to learn this and know if it's working, I'm too busy taking care of my patients. Yeah. Your point's well taken. Harry Glorikian: So great to speak to you. I look forward to continuing to read all the stuff that you produce and all these amazing, you know, technologies that you're constantly prolifically seem to be putting out there. And I'll let you know when the, when the, when my book is out, Michael Snyder: I definitely want to see it. Thank you. Harry Glorikian: Take care. Bye-bye.

Quelle voie d’abord privilégier ? Faut-il faire une exérèse de l’uretère distal ?Faut-il faire une ligature première de l’uretère ?Faut-il faire un curage ganglionnaire ? Faut-il faire une IPOP ?Le Dr Xylinas (CHU Bichat, Paris) répond à toutes vos questions ! L’orateur n’a pas reçu de rémunération pour la réalisation de cet épisode. Pour aller plus loin :https://www.urofrance.org/base-bibliographique/recommandations-francaises-du-comite-de-cancerologie-de-lafu-actualisation-15Recommandations actualisées 2020-2022 du Comité de Cancérologie de l’Association française d’Urologie (CCAFU) sur la prise en charge des tumeurs des voies excrétrices supérieureshttps://pubmed.ncbi.nlm.nih.gov/28903527/Efficacy of early ureteral ligation on prevention of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: a prospective single-arm multicenter clinical trial. Yamashita et al. 2017 Certaines données publiées peuvent ne pas avoir été validées par les autorités de santé françaises. La publication de ce contenu est effectuée sous la seule responsabilité de l’éditeur et de son comité scientifiqueMusique du générique : Via AudioNetworkResponsable projet AFUF : Dr Benjamin PradèreProduction : La Toile Sur Ecoute See acast.com/privacy for privacy and opt-out information.

Actor, writer, singer and multi-talented performer Francis Mabborang from the Philippines talks about his career and his journey in show business from Asia to New York starting with the International Presentation of Performers in L.A. plus performing at the World Trade Center in Manila and theatre work in NYC! Check out the amazing Francis Mabborang at www.francismabborang.com !

Amigas,La noventera más quirky y la mamá millenial top, está en YO Mujer. Tania Ibañez, es una ráfaga de sinceridad y amor bonito. Con una energía creativa y solidaria, nos comparte inputs de cómo empezar un proyecto personal, cómo creer en ti, y cómo balancear ser mamá sin perder tu esencia alocada. Todo esto en medio de referencias noventeras y mucha nostalgia por esos años de colores tornasol, pantiblusas y obvio tazos. Su proyecto iPop, está increible y lo puedes ver todos los Jueves en @tania_ibanez IGTV. Que disfrutes y recuerdes los noventas! Actívate, esto es #yomujer Support this show http://supporter.acast.com/yo-mujer. See acast.com/privacy for privacy and opt-out information.

Mesta prihodnosti se vračajo! Kaj vse se je v zadnjih treh mesecih zgodilo mestom, ki so bila med pandemijo središčne točke prenašanja okužb in hkrati prizorišča nekaterih najbolj dramatičnih prizorov, ki se bodo zapisali v kolektivno zavest človeštva? Z domačimi in tujimi strokovnjaki razmišljamo o tem, kako je izkušnja epidemije spremenila naše dojemanje javnih prostorov in infrastrukture, kako bomo preoblikovali prometne navade, kaj bo za mesta pomenil zaton turizma in kakšen bo nov odnos med mesti in podeželjem. Avtorja: Jan Grilc in dr. Dan Podjed (ZRC SAZU) Gosti: Steven Pedigo (Univerza Lyndona Johnsona, Teksas); Nicola Ussardi (Assemblea Sociale per la Casa, Benetke); dr. Maja Simoneti (Inštitut IPoP)

Nuestro amigo Toni Santaeularia aka Dj Bluetonic, tenía una cita ineludible con la buena música de club en La Casa de La Bomba ayer, debido a la situación actual no se pudo hacer. Pero decidió hacer igual su sesión en forma de WARM UP en exclusiva para emitirlo en iPOP. Dale al play y que siga vivo todo! :) www.ipopfm.com #bailadesdecasa #quedateencasa

La buena gente de La Negra Shop nos tenía que recomendar un disco, pero han hecho la crónica de una banda de punk de Alicante, Triple Ente. Así que si queréis saber más sobre esta banda y escuchar un tema, escuchad el audio. iPOP la #radioNOradio, más que una playlist

Nuestro amigo Toni Santaeularia aka Dj Bluetonic, tenía una cita ineludible con la buena música de club en La Casa de La Bomba ayer, debido a la situación actual no se pudo hacer. Pero decidió hacer igual su sesión en forma de WARM UP en exclusiva para emitirlo en iPOP. Dale al play y que siga vivo todo! :) www.ipopfm.com #bailadesdecasa #quedateencasa

La buena gente de La Negra Shop nos tenía que recomendar un disco, pero han hecho la crónica de una banda de punk de Alicante, Triple Ente. Así que si queréis saber más sobre esta banda y escuchar un tema, escuchad el audio. iPOP la #radioNOradio, más que una playlist

Hey Hey Hey! IPOP Family,  Welcome back, I know it has been a while since our last episode, but there needed to be some major changes made to the podcast world, and I figured why don't I be the one to bring those changes about,  We are changing a few things up because we didn't want to be another podcast show, someone you listen to while working out and or cooking your favorite meal, we wanted to bring a new sound to you here at IPOP, we want to make sure we bring you the very best experience possible to engage your mind, body and soul. tune and and tune up to what's in store,  We'll see you In Pursuit. Sincerely Marques Obeng Clark

Kako je nek prostor, mesto ali kraj urejen, kakšne možnosti ponuja prometna infrastruktura, kako zasnova javnih površin sooblikuje njihovo rabo, so vse ključni dejavniki, ki v pomembni meri določajo utrip nekega kraja in kvaliteto življenja v njem. Pod neposrednim pritiskom vse pogostejših vremenskih ekstremov, ki spremljajo podnebne spremembe, se danes v svetu vse več pozornosti namenja temu, da bi samo načrtovanje prostora upoštevalo temeljno soodvisnost narave, človeka in naših ekonomskih dejavnosti. Trajnostni urbanizem skuša te raznolike vidike smiselno preplesti ter tako postaviti boljše temelje za družbo prihodnosti. Toda čeprav se tudi pri nas beseda trajnostno veliko uporablja, pa dejanske prakse ne kažejo, da je do spremembe razmišljanja že prišlo. Kaj pravzaprav je trajnostni urbanizem in kaj nam lahko ponudi, smo se pogovarjali s krajinsko arhitektko in prostorsko načrtovalko dr. Majo Simoneti z Inštituta za politike prostora. Oddajo je pripravila Nina Slaček. foto: dr. Maja Simoneti (Matic Kos, Ipop)

Tercera emisión gumbo del programa con más soul, surf y rock 'n roll producido por The Reverend HotFoot Jackson en iPOP. En este programa ha sonado el siguiente tracklist: 01. Bill & Will - Goin' To The River 02. Lee Dresser - El Camino Real 03. Celia Cruz - Rock & Roll 04. Lalo Guerrero - Los Chucos Suaves 05. Barbara Lynn - Oh! Baby We Got A Good Thing Goin' 06. Mable John - Looking For A Man 07. Little Willie John - I'm Shakin' 08. James Brown - Good Lovin' 09. Johnny Otis - Castin' My Spell 10. The Strangeloves - Just The Way You Are 11. The Flower Children - Mini-Skirt Blues 12. The Teddy Boys - Jezebel 13. Ricky Nelson - Gypsy Woman 14. Ricky Nelson - Summertime 15. The Mark Four - Work All Day (Sleep All Night) 16. The Ravens - Sleepless Nights 17. Esquerita - Rockin' The Joint 18. Roy Gaines - Worried' Bout You Baby 19. Jack Scott - Stick Around Baby 20. Eddie Daniels - I Wanna Know 21. Trini Lopez - Fever 22. Ray Sharpe - Hey, Little Girl El programa se emite cada lunes a las 19h en www.ipopfm.com, +q1playlist. Be gumbo my friend

Tercera emisión gumbo del programa con más soul, surf y rock 'n roll producido por The Reverend HotFoot Jackson en iPOP. En este programa ha sonado el siguiente tracklist: 01. Bill & Will - Goin' To The River 02. Lee Dresser - El Camino Real 03. Celia Cruz - Rock & Roll 04. Lalo Guerrero - Los Chucos Suaves 05. Barbara Lynn - Oh! Baby We Got A Good Thing Goin' 06. Mable John - Looking For A Man 07. Little Willie John - I'm Shakin' 08. James Brown - Good Lovin' 09. Johnny Otis - Castin' My Spell 10. The Strangeloves - Just The Way You Are 11. The Flower Children - Mini-Skirt Blues 12. The Teddy Boys - Jezebel 13. Ricky Nelson - Gypsy Woman 14. Ricky Nelson - Summertime 15. The Mark Four - Work All Day (Sleep All Night) 16. The Ravens - Sleepless Nights 17. Esquerita - Rockin' The Joint 18. Roy Gaines - Worried' Bout You Baby 19. Jack Scott - Stick Around Baby 20. Eddie Daniels - I Wanna Know 21. Trini Lopez - Fever 22. Ray Sharpe - Hey, Little Girl El programa se emite cada lunes a las 19h en www.ipopfm.com, +q1playlist. Be gumbo my friend

In the latest episode of the Poynton, Webb dialogue on all things sustainable the pair discuss: the decision to disband the Indonesian Palm Oil Pledge, IPOP; IOI's decision to abandon their lawsuit against the RSPO, Resolute's decision to keep suing Green

En la programación de Verano de iPOP repasamos lo que sucederá en el Santander Music 2017. La programación, las zonas y todo lo que rodea al festival que se realizará el 3,4 y 5 de Agosto en Santander. Podéis vistar su página web para saber más y comprar los abonos y entradas: https://www.santandermusic.es www.ipopfm.com + q1playlist Facebook.com/ipopbroadcast // @ipop_radio (twitter) // @ipopfm (instagram) Síguenos y contacta con la mejor música que puedas escuchar ipopfm.radio@gmail.com (para contactar con nosotros)

En la programación de Verano de iPOP repasamos lo que sucederá en el Santander Music 2017. La programación, las zonas y todo lo que rodea al festival que se realizará el 3,4 y 5 de Agosto en Santander. Podéis vistar su página web para saber más y comprar los abonos y entradas: https://www.santandermusic.es www.ipopfm.com + q1playlist Facebook.com/ipopbroadcast // @ipop_radio (twitter) // @ipopfm (instagram) Síguenos y contacta con la mejor música que puedas escuchar ipopfm.radio@gmail.com (para contactar con nosotros)

Mike Snyder is well known in the genomics community for his iPOP (integrated personal omics profiling) study. Profiling himself with hundreds of thousands of measurements each day over a period of seven years and a group of a hundred others for about three years, he and his team at Stanford have shown that sequencing and other omics data can be used to predict Type II diabetes, cancer, heart problems and other disease. He’s also published numerous papers comparing NGS instruments. Now he is expanding iPOP with a whole new set of tools: over the counter wearable devices.

Saideh Browne - president of the National Council of Women of the United States at the United Nations - joins Jen Watterman for Women's History Month. No subject is off limits. The ladies discuss how No.45 lead women to step up and take a seat at the table of politics, why young people of color should visit the United Nations more often, and a whole lot more. If you're ready for a powerful, engaging conversation grab those headphones and click the play button.

Jen Watterman chats with Sherry Sims - founder and CEO of Black Career Women's Network - who shares how she stepped into her purpose after being burnt out from corporate America and couldn't find an ideal mentor. Take a listen to find out how Sims used her knowledge and skills to step into the nonprofit world and ultimately create BCWN, a national network dedicated to the professional development of Black-American women. And if you're thinking about starting your own business, be sure to pay close attention to Sims' advice, "Entrepreneurship isn't for everyone."

En motivo del concierto de Trajano! en Guadalajara, nuestro colaborador Jorge (YO TAMBIEN SOY INDIE), realizó esta entrevista, que se emitirá en el programa POPLAROID. Yo También Soy Indie es un grupo de seguidores de la música "indie" o independiente, british y derivados. Adictos a los conciertos y festivales del género. Más info: https://www.facebook.com/pages/Yo-tambien-soy-indie/804616216233102

En motivo del concierto de Trajano! en Guadalajara, nuestro colaborador Jorge (YO TAMBIEN SOY INDIE), realizó esta entrevista, que se emitirá en el programa POPLAROID. Yo También Soy Indie es un grupo de seguidores de la música "indie" o independiente, british y derivados. Adictos a los conciertos y festivales del género. Más info: https://www.facebook.com/pages/Yo-tambien-soy-indie/804616216233102

En los conciertos que retransmite iPOP, pasaron los Wednesday Lips presentando el nuevo álbum SEASON III Mònica Guiteras, Albert Gilabert y Pol Alonso forman un trío pop-folk con sonoridades muy interesantes. Tracklist: 1.- Fun And Tragedy. 2.- Swim it! 3.- Trousers. 4.- Godspeed. 5.- Driving too fast (I). 6.- Driving too fast (II). 7.- Rage. 8.- Respect. 9.- Land, Land, Land. 10.- Wonderwall. 11.- Snowball. 12.- Carrers Estrets. 13.- Dysfunctional System. 14.- When Mothers Leave The Room. 15.- Caramel. Grabado en el Café Teatre de Lleida, 28 de diciembre de 2014. + info: https://www.facebook.com/pages/Wednesday-Lips/233450688449?fref=ts @wednesdaylips

En los conciertos que retransmite iPOP, pasaron los Wednesday Lips presentando el nuevo álbum SEASON III Mònica Guiteras, Albert Gilabert y Pol Alonso forman un trío pop-folk con sonoridades muy interesantes. Tracklist: 1.- Fun And Tragedy. 2.- Swim it! 3.- Trousers. 4.- Godspeed. 5.- Driving too fast (I). 6.- Driving too fast (II). 7.- Rage. 8.- Respect. 9.- Land, Land, Land. 10.- Wonderwall. 11.- Snowball. 12.- Carrers Estrets. 13.- Dysfunctional System. 14.- When Mothers Leave The Room. 15.- Caramel. Grabado en el Café Teatre de Lleida, 28 de diciembre de 2014. + info: https://www.facebook.com/pages/Wednesday-Lips/233450688449?fref=ts @wednesdaylips

Concierto que ofrecieron la banda de Lleida, Foo en el Café Teatro, en el cual concluye la gira Parallel Lives. Tracklist: 01.- Intro 02.- Those That Die Young 03.- Time To Create From The Chaos 04.- Amazement 05.- Whisky Breakfast 06.- Merry Maker 07.- Rinku Star 08.- Camouflage + Savoir Faire 09.- Fenicottero 10.- Crows 11.- Remorseless 12.- My New Friend 13.- Frenemies 14.- Call of the Wild ---------------------------- 15.- From Vampires, From The Pain 16.- One Day, Three Cities 17.- The Rain + info: http://fooband.bandcamp.com/ https://www.facebook.com/pages/Who-is-FOO/198348780178286 Grabación - Café Teatre de Lleida. Edición - iPop

Concierto que ofrecieron la banda de Lleida, Foo en el Café Teatro, en el cual concluye la gira Parallel Lives. Tracklist: 01.- Intro 02.- Those That Die Young 03.- Time To Create From The Chaos 04.- Amazement 05.- Whisky Breakfast 06.- Merry Maker 07.- Rinku Star 08.- Camouflage + Savoir Faire 09.- Fenicottero 10.- Crows 11.- Remorseless 12.- My New Friend 13.- Frenemies 14.- Call of the Wild ---------------------------- 15.- From Vampires, From The Pain 16.- One Day, Three Cities 17.- The Rain + info: http://fooband.bandcamp.com/ https://www.facebook.com/pages/Who-is-FOO/198348780178286 Grabación - Café Teatre de Lleida. Edición - iPop

Podcast del programa que se dedica a hacer una repasada a los temas independientes más destacados, así como entrevistar a bandas emergentes. En este programa se ha entrevistado a Black Islands, una banda con mucha proyección y cuyo albúm es mas que destacable. Poplaroid se emite Alpicat Ràdio cada martes de 23 a 24h y en iPop, cada miercoles de 21 a 22h.

Podcast del programa que se dedica a hacer una repasada a los temas independientes más destacados, así como entrevistar a bandas emergentes. En este programa se ha entrevistado a Black Islands, una banda con mucha proyección y cuyo albúm es mas que destacable. Poplaroid se emite Alpicat Ràdio cada martes de 23 a 24h y en iPop, cada miercoles de 21 a 22h.

E na mansão Wayne: Bem vindos, muito bem vindos a mais um United Cast, o podcast mais sem o DS da internet. Sim, neste episódio novamente não tivemos a presença do chefe, porque O DS ERRAAAAAA e ficou sem computador por uns dias. Sem tal presença endiabrada, os podcasters Leon, […]

Madrass Podcast Epizod 75 – Rap kréyol ki soti Ayiti. Bon siwotaj, Missié Geez. PLAYLIST Rockfam – Afichéw Dro Baller – Let’s Go K.Libr – Rap Salad Wendyyy Traka – Yo Mélé I.E.T – Tet Grenn Tragedy – Revolution Rockfam – Pou Yo Rockfam – I’m from the hood Rockfam – Nou Sanblé Rockfam – […]

Madrass Podcast Epizod 72 – Rap kréyol ki soti Ayiti ek Gwadloup. Bon siwotaj, Missié Geez. PLAYLIST Setcha ft Dug G – Kouman Nou yé Baky – Fe’m Konfians Barikad Crew – Bafon Plafon (feat Rutchelle) Mik – Fast Love Mik – Tempo Love Zatrap ft Triple J – Lè Yon Fanm Damou Barikad Crew […]

Madrass Podcast Epizod 65 – Rap kréyol ki soti Ayiti, Gwadloup ek Matinik. Bon siwotaj, Missié Geez. PLAYLIST Barikad Crew – Jump! Barikad Crew – Ewo (ft Rutshelle) Trajik – The King is Back Nicy – Milié Nicy – I Lou Abojah – Pran San’m Abojah – Trip Mik – Teddy Riner Mik – Categorie […]

Podcast 57 - A Volta dos que não foramNessa edição, Diogo (@diogocscooby) e Thiago (@serial_newkid) comentam as notícias mais relevantes dos últimos tempos da última semana.Saiba o porquê do desaparecimento de um dos membros da equipe, conheça mais sobre algumas taras, um novo possível esporte olímpico, a alta tecnologia no Brasil, uma opção mais barata de Iphone e muito mais nessa edição do podcast regada de boa música e com algumas palavras do grande Mestre Alborghetti.Nosso email é:cadeia@cachorrosolitario.comDivirta-se: Ou então baixe o arquivo no formato ZIP ou no formato MP3. (Clique com o botão direito do mouse e vá em "salvar destino como...)Comentado no Episódio:Tormenta da vezPiranhas jovens disputam competicao de trenó na neve de ToplessCybrog IVTarado por borrachaIpopNovo acessório permite o uso do iphone para falarANTIGAS NOVIDADES! (Muito Legal) por matmarley2005 no Videolog.tv.----

Hosts: Vincent Racaniello and Rich Condit Vincent and Rich discuss recovery of a hepatitis B viral genome from a 16th century Korean mummy, and personal omics profiling of an individual over a 14 month period. Links for this episode: Tracing HBV to the 16th century (Hepatology) HBV on TWiV Precautions with ancient DNA (Science) Personal omics profile over 14 months (Cell) A geneticist's research turns personal (NY Times) Mike Snyder on Futures in Biotech The DASH diet TWiV on Facebook Letters read on TWiV 187 Weekly Science Picks Rich - The Checklist by Atul GawandeVincent - Artologica Listener Pick of the Week David - Cracking your genetic code (Nova)Josh - The nuclearization of biology is a threat to health and security (pdf) Send your virology questions and comments (email or mp3 file) to twiv@twiv.tv, or call them in to 908-312-0760. You can also post articles that you would like us to discuss at microbeworld.org and tag them with twiv.